var title_f9_30_9696="Herpetic whitlow finger";
var content_f9_30_9696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpetic whitlow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9696=[""].join("\n");
var outline_f9_30_9696=null;
var title_f9_30_9697="Scabies buttocks";
var content_f9_30_9697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules are present on the buttocks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9697=[""].join("\n");
var outline_f9_30_9697=null;
var title_f9_30_9698="Colonoscopy";
var content_f9_30_9698=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Colonoscopy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/30/9698/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9698/contributors\" id=\"au4491\">",
"       Jerome D Waye, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/30/9698/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9698/contributors\" id=\"se5275\">",
"       John R Saltzman, MD, FACP, FACG, FASGE",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/30/9698/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9698/contributors\" id=\"de2797\">",
"       Anne C Travis, MD, MSc, FACG",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?9/30/9698?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COLONOSCOPY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     A colonoscopy is an exam of the lower part of the gastrointestinal tract, which is called the colon or large intestine (bowel). Colonoscopy is a safe procedure that provides information other tests may not be able to give. Patients who require colonoscopy often have questions and concerns about the procedure.",
"    </p>",
"    <p>",
"     Colonoscopy is performed by inserting a device called a colonoscope into the anus and advanced through the entire colon (",
"     <a class=\"graphic graphic_figure graphicRef58531 \" href=\"UTD.htm?12/60/13250\">",
"      figure 1",
"     </a>",
"     ). The procedure generally takes between 20 minutes and one hour.",
"    </p>",
"    <p>",
"     Other tests that are sometimes used to screen for colon cancer, like virtual colonoscopy (also called CT colonography), are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about colonoscopy is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link\">",
"      \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REASONS FOR COLONOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     The most common reasons for colonoscopy are to evaluate the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       As a screening exam for polyps or colon cancer",
"      </li>",
"      <li>",
"       Rectal bleeding",
"      </li>",
"      <li>",
"       A change in bowel habits, like persistent diarrhea",
"      </li>",
"      <li>",
"       Iron deficiency anemia (a decrease in blood count due to loss of iron)",
"      </li>",
"      <li>",
"       A family history of colon cancer",
"      </li>",
"      <li>",
"       As a follow-up test in people with colon polyps or colon cancer",
"      </li>",
"      <li>",
"       Chronic, unexplained abdominal or rectal pain",
"      </li>",
"      <li>",
"       An abnormal x-ray exam, like a barium enema or CT scan",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      COLONOSCOPY PREPARATION",
"     </span>",
"    </p>",
"    <p>",
"     Before colonoscopy, your colon must be completely cleaned out so that the doctor can see any abnormal areas. Your doctor's office will provide specific instructions about how you should prepare for colonoscopy. Be sure to read these instructions as soon as you get them so you will know how to take the preparation and to find out if you need to make any changes to your medications or diet. If you have questions, call the doctor's office in advance.",
"    </p>",
"    <p>",
"     You will need to avoid solid food for at least one day before the test. You should also drink plenty of fluids on the day before the test. You can drink clear liquids up to several hours before your procedure, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Water",
"      </li>",
"      <li>",
"       Clear broth (beef, chicken, or vegetable)",
"      </li>",
"      <li>",
"       Coffee or tea (without milk)",
"      </li>",
"      <li>",
"       Ices",
"      </li>",
"      <li>",
"       Gelatin such as Jell-o (avoid red gelatin)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     To clean the colon, you will take a strong laxative and empty your bowels. You may be asked to take the entire preparation the night before the test, or you may be asked to take it in two doses, with the second dose taken four to six hours prior to the colonoscopy. Giving the preparation in two \"split\" doses may help get the colon even cleaner. This may require you to awaken early in the morning to complete the preparation. The instructions you are given will tell you how you should take the preparation.",
"    </p>",
"    <p>",
"     A commonly used preparation is a 4-liter (1 gallon) solution that is purchased at the pharmacy. There are several 2-liter (half-gallon) preparations on the market as well. Some doctors prefer citrate of magnesia (also called magnesium citrate), a 300 cc (10 ounce) bottle that requires no mixing. Packets of powdered laxative are available that are mixed with a smaller volume of water. Special laxative pills are available but may not be safe for some patients and require that you contact your doctor for this advice.",
"    </p>",
"    <p>",
"     Refrigerating the solution can make it easier to drink, but do not put ice in the solution since it will melt and you will have to drink even more fluid. Drinking the solution through a straw may also make it easier to drink. Drinking this solution may be the most unpleasant part of the exam. Watery diarrhea is the desired result. This may occur shortly after drinking the solution or may be delayed for several hours. If you become nauseated or vomit while drinking the solution, call your doctor or nurse for instructions. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"      \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;You can take most prescription and nonprescription medicines right up to the day of the colonoscopy. Your doctor should tell you what medicines to stop. You should also tell the doctor if you are allergic to any medicines.",
"    </p>",
"    <p>",
"     Some medicines increase the risk of heavy bleeding if you have a polyp removed during the colonoscopy. Ask your doctor how and when to stop these medicines, including",
"     <span class=\"nowrap\">",
"      warfarin/Coumadin,",
"     </span>",
"     <span class=\"nowrap\">",
"      clopidogrel/Plavix,",
"     </span>",
"     or any other anticoagulant medicine. Do not stop these medications without first talking with your doctor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Transportation home",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most patients are given a sedative (a medicine to help you relax) during the colonoscopy, so you will need someone to take you home after your test. Your doctor may prefer that an anesthesiologist administer the sedative and monitor you during the colonoscopy. Although you will be awake by the time you go home, the",
"     <span class=\"nowrap\">",
"      sedative/anesthetic",
"     </span>",
"     medicines cause changes in reflexes and judgment that can interfere with your ability to make decisions, similar to the effect of alcohol. You will not be able to drive home or go back to work after the examination if you received sedation for the procedure. You should be able to return to work the next day.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      WHAT TO EXPECT",
"     </span>",
"    </p>",
"    <p>",
"     Before the test, a doctor will review the procedure with you, including possible complications, and will ask you to sign a consent form.",
"    </p>",
"    <p>",
"     An IV line will be inserted in your hand or arm. Your blood pressure and heart rate will be monitored during the test",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      THE COLONOSCOPY PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     You will be given fluid and medicines through the IV line. With",
"     <span class=\"nowrap\">",
"      sedation/analgesia",
"     </span>",
"     provided by the colonoscopist, many people sleep during the test, while others are very relaxed, comfortable, and generally not aware. Your doctor may request an anesthesiologist give you an anesthetic agent (Propofol), which is a stronger sedative and will put you to sleep while you are being closely monitored.",
"    </p>",
"    <p>",
"     The colonoscope is a flexible tube, approximately the diameter of the index finger. The scope gently pumps air into the colon to inflate it and allow the doctor to see the entire lining. You might feel bloating or gas cramps as the air opens the colon. Try not to be embarrassed about passing this gas (it is just air), and let your doctor know if you are uncomfortable.",
"    </p>",
"    <p>",
"     During the procedure, the doctor might take a biopsy (small pieces of tissue) or remove polyps. Polyps are growths of tissue that can range in size from the tip of a pen to several inches. Most polyps are benign (not cancerous). However, some polyps can become cancerous if allowed to grow for a long time. Having a polyp removed does not hurt. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"      \"Patient information: Colon polyps (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link\">",
"      \"Endoscopic removal of large colonic polyps\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      RECOVERY FROM COLONOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     After the colonoscopy, you will be observed in a recovery area until the effects of the sedative medication wear off. The most common complaint after colonoscopy is a feeling of bloating and gas cramps. You may also feel groggy from the sedation medications. You should not return to work or drive that day. Most people are able to eat normally after the test. Ask your doctor when it is safe to restart aspirin and other blood-thinning medications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      COLONOSCOPY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Colonoscopy is a safe procedure, and complications are rare but can occur:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bleeding can occur from biopsies or the removal of polyps, but it is usually minimal and can be controlled.",
"      </li>",
"      <li>",
"       The colonoscope can cause a tear or hole in the colon. This is a serious problem, but it does not happen commonly.",
"      </li>",
"      <li>",
"       It is possible to have side effects from the sedative medicines.",
"      </li>",
"      <li>",
"       Although colonoscopy is the best test to examine the colon, it is possible for even the most skilled doctors to miss or overlook an abnormal area in the colon.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You should call your doctor immediately if you have any of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Severe abdominal pain (not just gas cramps)",
"      </li>",
"      <li>",
"       A firm, bloated abdomen",
"      </li>",
"      <li>",
"       Vomiting",
"      </li>",
"      <li>",
"       Fever",
"      </li>",
"      <li>",
"       Rectal bleeding (greater than a couple of tablespoons [30 mL])",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      AFTER COLONOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     Although many people worry about being uncomfortable during a colonoscopy, most people tolerate it very well and feel fine afterward. It is normal to feel tired afterward. Plan to take it easy and relax the rest of the day.",
"    </p>",
"    <p>",
"     Your doctor can describe the results of the colonoscopy as soon as it is over. If",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     took biopsies or polyps, you should call for results within one to two weeks.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our Web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050794\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050801\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=see_link\">",
"      Patient information: GI bleed (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=see_link\">",
"      Patient information: Angiodysplasia of the GI tract (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/47/21234?source=see_link\">",
"      Patient information: Familial adenomatous polyposis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/36/25154?source=see_link\">",
"      Patient information: Microscopic colitis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050815\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"      Patient information: Colon polyps (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050860\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11304?source=see_link\">",
"      Bleeding after colonic polypectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link\">",
"      Endoscopic removal of large colonic polyps",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=see_link\">",
"      Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42694?source=see_link\">",
"      Sedation-free gastrointestinal endoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30519?source=see_link\">",
"      Tattooing and other methods for localizing colonic lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/colonoscopy.html\">",
"      www.nlm.nih.gov/medlineplus/colonoscopy.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society for Gastrointestinal Endoscopy",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.asge.org/PatientInfoIndex.aspx?id=382\">",
"      www.asge.org/PatientInfoIndex.aspx?id=382",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?9/30/9698/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?9/30/9698?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9698/abstract/1\">",
"      Belsey J, Crosta C, Epstein O, et al. Meta-analysis: the relative efficacy of oral bowel preparations for colonoscopy 1985-2010. Aliment Pharmacol Ther 2012; 35:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9698/abstract/2\">",
"      Blero D, Devi&egrave;re J. Endoscopic complications--avoidance and management. Nat Rev Gastroenterol Hepatol 2012; 9:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9698/abstract/3\">",
"      ASGE Standards of Practice Committee, Early DS, Ben-Menachem T, et al. Appropriate use of GI endoscopy. Gastrointest Endosc 2012; 75:1127.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f9_30_9698=[""].join("\n");
var outline_f9_30_9698=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COLONOSCOPY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REASONS FOR COLONOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           COLONOSCOPY PREPARATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           WHAT TO EXPECT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           THE COLONOSCOPY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           RECOVERY FROM COLONOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           COLONOSCOPY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           AFTER COLONOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13250\" title=\"figure 1\">",
"           Diagram colon rectum PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f9_30_9699="Azelaic acid: Pediatric drug information";
var content_f9_30_9699=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azelaic acid: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"    see \"Azelaic acid: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/34/18980?source=see_link\">",
"    see \"Azelaic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azelex&reg;;",
"     </li>",
"     <li>",
"      Finacea&reg;;",
"     </li>",
"     <li>",
"      Finacea&reg; Plus&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Finacea&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"      see \"Azelaic acid: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acne vulgaris: Children &gt;12 years and Adults: Apply 20% azelaic acid twice daily in the morning and evening; may reduce to once daily if persistent skin irritation occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rosacea: Adults: Apply 15% azelaic acid gel to affected areas of the face twice daily in the morning and evening",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azelex&reg;: 20% (30 g, 50 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Finacea&reg;: 15% (50 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Finacea&reg; Plus&trade;: 15% (50 g [DSC]) [contains benzoic acid; packaged with cleanser and lotion]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: After skin is thoroughly washed with a mild soap or a soapless cleansing lotion and patted dry, apply a thin film and massage into the affected area. Wash hands following application.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of mild to moderate acne vulgaris; treatment of inflammatory papules and pustules of mild to moderate rosacea",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F138343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne (gel), burning/stinging/tingling, contact dermatitis, dry skin/peeling/scaling/xerosis, edema (gel), erythema, irritation, pruritus (gel)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Asthma exacerbation, allergic reaction, dermatitis, herpes labialis exacerbation, hypertrichosis, iridocyclitis, rash, reddening, small depigmented spots, vitiligo depigmentation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azelaic acid, propylene glycol, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to isolated reports of hypopigmentation, use cautiously in patients with dark complexions; for topical use only; avoid contact with eyes, mouth, mucous membranes, or open wounds",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cream and gel contain benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; do not use in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13276947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies following oral administration. Minimal systemic absorption (&lt;4%) occurs following topical administration.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction in lesion size and/or inflammation; reduction in the number of lesions",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Azelaic acid is a dietary constituent of whole grain cereals and animal products; its exact mechanism of action has not been determined; azelaic acid possesses antimicrobial activity against",
"     <i>",
"      Propionibacterium acnes",
"     </i>",
"     and",
"     <i>",
"      Staphylococcus epidermidis",
"     </i>",
"     ; normalization of keratinization leading to an anticomedonal effect may also contribute to its clinical activity",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1045403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 1-4 months",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &sim;3% to 5% penetrates stratum corneum; up to 10% found in epidermis and dermis; 4% systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily unchanged in the urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/34/18980?source=see_link\">",
"      see \"Azelaic acid: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes, mouth, mucous membranes, or open wounds. Avoid use of alcoholic skin cleansers, tinctures, and astringents, abrasives and peeling agents. Do not apply occlusive dressings; temporary skin irritation may occur when applied to broken or inflamed skin, usually at the start of treatment; report abnormal changes in skin color or persistent skin irritation to the healthcare provider. Gel: Avoid spicy foods, thermally hot foods and drinks, and alcoholic beverages that might cause erythema, flushing, or blushing.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13259 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9699=[""].join("\n");
var outline_f9_30_9699=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138303\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663156\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045398\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045391\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138288\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138276\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045401\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045394\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045400\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138343\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045405\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045390\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045389\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298802\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218206\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138285\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276947\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045397\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045388\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045403\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045404\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045396\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13259|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=related_link\">",
"      Azelaic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/34/18980?source=related_link\">",
"      Azelaic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_30_9700="Transperineal fistula repair4";
var content_f9_30_9700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior rectal wall defect is closed longitudinally with interrupted 4-0 delayed absorbable sutures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9700=[""].join("\n");
var outline_f9_30_9700=null;
var title_f9_30_9701="Vitamin D3 (cholecalciferol): Patient drug information";
var content_f9_30_9701=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin D3 (cholecalciferol): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38725?source=see_link\">",
"     see \"Vitamin D3 (cholecalciferol): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/4/33862?source=see_link\">",
"     see \"Vitamin D3 (cholecalciferol): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bio-D-Mulsion Forte&reg; [OTC];",
"     </li>",
"     <li>",
"      Bio-D-Mulsion&reg; [OTC];",
"     </li>",
"     <li>",
"      D-3 [OTC];",
"     </li>",
"     <li>",
"      D3-50&trade; [OTC];",
"     </li>",
"     <li>",
"      D3-5&trade; [OTC];",
"     </li>",
"     <li>",
"      DDrops&reg; Baby [OTC];",
"     </li>",
"     <li>",
"      DDrops&reg; Kids [OTC];",
"     </li>",
"     <li>",
"      DDrops&reg; [OTC];",
"     </li>",
"     <li>",
"      Delta&reg; D3 [OTC];",
"     </li>",
"     <li>",
"      Enfamil&reg; D-Vi-Sol&trade; [OTC];",
"     </li>",
"     <li>",
"      Maximum D3&reg; [OTC];",
"     </li>",
"     <li>",
"      Vitamin D3 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      D-Vi-Sol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12676145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691538",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat vitamin D deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cholecalciferol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701372",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a malabsorption syndrome or too much vitamin D or calcium in your body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697244",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had high calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of vitamin D.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take cholestyramine, mineral oil, antacids that have magnesium, or orlistat with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High calcium level. Signs include weakness, confusion, feeling tired, headache, upset stomach and throwing up, hard stools (constipation), or bone pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12108 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9701=[""].join("\n");
var outline_f9_30_9701=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150802\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150803\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12676145\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022420\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022419\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022424\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022425\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022427\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022422\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022423\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022428\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022429\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38725?source=related_link\">",
"      Vitamin D3 (cholecalciferol): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/4/33862?source=related_link\">",
"      Vitamin D3 (cholecalciferol): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_30_9702="Streptozocin: Drug information";
var content_f9_30_9702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Streptozocin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/18/11557?source=see_link\">",
"    see \"Streptozocin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zanosar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zanosar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pancreatic islet cell carcinoma, metastatic:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Daily schedule:",
"     </i>",
"     500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 consecutive days every 6 weeks until maximum benefit or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Weekly schedule:",
"     </i>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly; if therapeutic response not achieved after 2 weeks, may escalate dose to a maximum of 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unlabeled dosing:",
"     </i>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 3 weeks for up to 6 cycles (in combination with leucovorin, fluorouracil and cisplatin) (Turner, 2010)",
"     <b>",
"      or",
"     </b>",
"     400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 to 5 every 4 weeks (in combination with fluorouracil and doxorubicin) until disease progression or unacceptable toxicity (Kouvaraki, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adrenal carcinoma, metastatic (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg once daily for 5 days (cycle 1) followed by 2000 mg on day 1 (subsequent cycles) every 3 weeks (in combination with mitotane) (Fassnacht, 2012; Khan 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in obesity:",
"     </b>",
"     <i>",
"      ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:",
"     </i>",
"     Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Select dose cautiously, beginning at the lower end of dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F223275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, it is recommended to use clinical judgment weighing benefit vs risk of renal toxicity in patients with pre-existing renal impairment. The following dosing adjustments have been recommended (Aronoff, 2007): Adults (based on a usual dose of 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F223276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling. Streptozocin is rapidly hepatically metabolized; dose should be decreased in patients with severe liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F16329371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      Bone marrow suppression or hepatic dysfunction:",
"     </i>",
"     May require dosage reduction or discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zanosar&reg;: 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F223254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as either a rapid I.V. injection",
"     <b>",
"      or",
"     </b>",
"     as short or prolonged infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F223298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, etoposide phosphate, filgrastim, gemcitabine, granisetron, melphalan, ondansetron, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, aztreonam,  piperacillin/tazobactam.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic islet cell carcinoma of the pancreas (symptomatic or progressive disease)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9349144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic adrenal carcinoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Streptozocin may be confused with streptomycin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Glucose intolerance, hyper-/hypoglycemia, hypoalbuminemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LDH increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (burning, edema, erythema, inflammation, irritation, tenderness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Anuria, azotemia, BUN increased, creatinine increased, glycosuria, nephrotoxicity, proteinuria, renal dysfunction, renal tubular acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infrequent, postmarketing, and/or case reports: Anemia, confusion, depression, diabetes insipidus, lethargy, leukopenia, myelosuppression (nadir: at 2-3 weeks), secondary malignancies, thrombocytopenia, liver dysfunction, secondary malignancy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Hematologic toxicity has been observed.",
"     </b>",
"     Mild bone marrow suppression (rare) may occur; monitor blood counts weekly. May require dosage reduction or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause confusion, lethargy or depression; caution patients about performing tasks that require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: Diarrhea has been observed. May cause severe nausea and vomiting.",
"     </b>",
"     Potential for nausea and vomiting is high; antiemetic premedication is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose intolerance: Mild-to-moderate glucose intolerance may occur; generally is reversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Liver dysfunction has been observed.",
"     </b>",
"     Hepatotoxicity may be characterized by elevated transaminases and LDH, or by hypoalbuminemia; monitor liver function weekly. Hepatic dysfunction may require dosage reduction or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Renal toxicity is dose-related and cumulative; may be severe or fatal.",
"     </b>",
"     Azotemia, anuria, hypophosphatemia, glycosuria and renal tubular acidosis have been reported. Adequate hydration may reduce the risk for nephrotoxicity. Monitor renal function (BUN, serum creatinine, and serial urinalysis) and electrolytes prior to, weekly during, and after each treatment course. Mild proteinuria is an early sign of renal toxicity; if proteinuria is detected with urinalysis, obtain 24-hour urine collection. Avoid use in combination with other nephrotoxic medications. Use with caution in patients with pre-existing renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Streptozocin is mutagenic; parenteral use is tumorigenic and carcinogenic in animals.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician. Administer in a facility with sufficient access to lab and supportive resources for monitoring toxicities.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation/tissue irritation: Streptozocin is an irritant with vesicant-like properties. Local tissue irritation or inflammation (burning, edema, erythema, tenderness) may occur, but usually resolves within a few days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F223282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16328885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if streptozocin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Zanosar Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $349.23",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F223249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function tests, including BUN, serum creatinine, and serial urinalysis, and serum electrolytes (at baseline, weekly during, and for 4 weeks after treatment); 24-hour urine collection if proteinuria is detected on urinalysis; liver function tests (weekly), CBC with differential and platelets (weekly), blood glucose; monitor infusion site",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F223259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Zanosar (CH, FR, GR, IL, NL, NO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA synthesis by alkylation and cross-linking the strands of DNA, and by possible protein modification; cell cycle nonspecific",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset: 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly: Onset of response: 17 days; median time to maximum response: 35 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Concentrates in liver, kidney, and pancreatic beta cells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapid; primarily hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: &lt;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily; as parent drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 101.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bolzan AD and Bianchi MS, &ldquo;Genotoxicity of Streptozotocin,&rdquo;",
"      <i>",
"       Mutat Res",
"      </i>",
"      , 2002, 512(2-3):121-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/30/9702/abstract-text/12464347/pubmed\" id=\"12464347\" target=\"_blank\">",
"        12464347",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fassnacht M, Terzolo M, Allolio B, et al, &ldquo;Combination Chemotherap in Advanced Adrenocortical Carcinoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(23):2189-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/30/9702/abstract-text/22551107/pubmed\" id=\"22551107\" target=\"_blank\">",
"        22551107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(13):1553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/30/9702/abstract-text/22473167/pubmed\" id=\"22473167\" target=\"_blank\">",
"        22473167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan TS, Imam H, Juhlin C, et al, &ldquo;Streptozocin and o,p'ddd in the Treatment of Adrenocortical Cancer Patients: Long-Term Survival in Its Adjuvant Use,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2000, 11(10):1281-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/30/9702/abstract-text/11106117/pubmed\" id=\"11106117\" target=\"_blank\">",
"        11106117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kouvaraki MA, Ajani JA, Hoff P, et al, &ldquo;Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(23):4762-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/30/9702/abstract-text/15570077/pubmed\" id=\"15570077\" target=\"_blank\">",
"        15570077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/30/9702/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turner NC, Strauss SJ, Sarker D, et al, &ldquo;Chemotherapy With 5-Fluorouracil, Cisplatin and Streptozocin for Neuroendocrine Tumours,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2010, 102(7):1106-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/30/9702/abstract-text/20234360/pubmed\" id=\"20234360\" target=\"_blank\">",
"        20234360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9949 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9702=[""].join("\n");
var outline_f9_30_9702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709419\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223269\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223270\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223293\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223273\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223274\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223275\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223276\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16329371\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223251\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223235\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223254\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223298\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223252\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349144\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223299\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223291\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223257\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223239\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300083\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223244\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223246\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079772\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223282\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328885\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323893\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223249\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223259\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223238\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223256\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9949\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9949|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/18/11557?source=related_link\">",
"      Streptozocin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_30_9703="Lichen planopilaris with erythema";
var content_f9_30_9703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lichen planopilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scarring alopecia due to lichen planopilaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Ginat Mirowski.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9703=[""].join("\n");
var outline_f9_30_9703=null;
var title_f9_30_9704="Prostate cancer: Risk stratification, other prognostic factors, and predictive tools";
var content_f9_30_9704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/30/9704/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9704/contributors\">",
"     Eric A Klein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/30/9704/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9704/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9704/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9704/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/30/9704/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9704/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/30/9704/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is the second most common cancer in men worldwide, with an estimated 900,000 cases and 258,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/1\">",
"     1",
"    </a>",
"    ]. In developed areas, prostate cancer is increasingly being diagnosed when the tumor is confined to the prostate, due at least in part to screening with prostate specific antigen (PSA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link&amp;anchor=H27#H27\">",
"     \"Screening for prostate cancer\", section on 'Evidence from observational studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For men with newly diagnosed prostate cancer, the most important factors in selecting a treatment approach include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic extent of disease (tumor, node, metastasis)",
"     </li>",
"     <li>",
"      Histologic grade (Gleason score) of the tumor",
"     </li>",
"     <li>",
"      Serum PSA level",
"     </li>",
"     <li>",
"      Estimated outcome with different treatment options",
"     </li>",
"     <li>",
"      Potential complications with each treatment approach",
"     </li>",
"     <li>",
"      The patient's general medical condition, age, and comorbidity, as well as individual preferences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk stratification and prognostic factors for men with newly diagnosed prostate cancer are presented here. The clinical presentation and initial evaluation of these men are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23527?source=see_link\">",
"     \"Initial staging and evaluation of men with newly diagnosed prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11494930\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of men with newly diagnosed prostate cancer needs to incorporate a consideration of the prolonged natural history of the disease and the risk for progression to disseminated, potentially fatal disease.",
"   </p>",
"   <p>",
"    The initial evaluation should include clinical staging based upon digital rectal examination by an experienced clinician to assess the extent of disease, the pretreatment serum PSA, the Gleason score in the initial biopsy, and the number of biopsy cores involved by cancer. Imaging studies (radionuclide bone scan, CT of the abdomen and pelvis, endorectal coil MRI) are used selectively to assess for extraprostatic extension, regional adenopathy, or distant metastases depending upon the initial clinical staging (",
"    <a class=\"graphic graphic_figure graphicRef80052 \" href=\"UTD.htm?14/59/15281\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23527?source=see_link\">",
"     \"Initial staging and evaluation of men with newly diagnosed prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard staging system for newly diagnosed prostate cancer is that of the AJCC",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    UICC (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ). This system incorporates the anatomic extent of disease, including the primary tumor (T), regional lymph nodes (N), and distant metastases (M). The 2010 update of this system incorporates the pretreatment serum prostate specific antigen (PSA) and Gleason score to divide patients into prognostic categories. This information about prognostic categories is also combined with patient age, life expectancy, overall medical condition including performance status and comorbidities, the presence or absence of symptoms, and patient preferences to make decisions for the optimal treatment for an individual patient.",
"   </p>",
"   <p>",
"    Factors that need to be considered in relying upon clinical staging include variability in the interpretation of the findings on digital rectal examination, variability in assigning the Gleason grade on the biopsy, and sampling errors in the prostate biopsy that may lead to missing areas with a Gleason pattern 4 or 5.",
"   </p>",
"   <p>",
"    The initial evaluation provides the information for clinical staging as distinct from pathologic staging and forms the basis for the initial treatment decisions. For patients who undergo radical prostatectomy, additional information is obtained from the pathologic specimen, and this forms the basis for pathologic staging. Clinical staging may significantly under or overestimate the extent of disease. When pathologic staging reveals important poor prognosis features (higher Gleason grade, extracapsular extension, seminal vesicle involvement, or lymph node involvement) additional therapy may be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23527?source=see_link&amp;anchor=H686719716#H686719716\">",
"     \"Initial staging and evaluation of men with newly diagnosed prostate cancer\", section on 'Clinical versus pathologic staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following treatment recommendations based upon risk stratification are consistent with guidelines from the American Urological Association (AUA) and the National Comprehensive Cancer Network [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4280895\">",
"    <span class=\"h2\">",
"     Clinically localized, very low risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with very low risk prostate cancer have disease detected by prostate biopsy based upon serum PSA only, without detectable abnormality on digital rectal examination or imaging. To be classified as very low risk, such patients must have a Gleason score of 6 or less on biopsy and a serum PSA &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Furthermore, the extent of disease within the prostate must be limited (ie, fewer than three positive biopsy cores with less than 50 percent involvement in any one core, and a PSA density less than 0.15",
"    <span class=\"nowrap\">",
"     ng/mL/gram)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active surveillance is usually recommended for men with very low risk disease and a life expectancy less than 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/3\">",
"     3",
"    </a>",
"    ]. For men with a longer life expectancy, the treatment options are the same as those men with clinically localized, low risk disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11494937\">",
"    <span class=\"h2\">",
"     Clinically localized, low risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with low risk, clinically localized prostate cancer either have no apparent tumor in the prostate (ie, diagnosis based upon a biopsy only, with no abnormal findings on imaging or palpation) or limited disease in one lobe of the prostate gland, a serum PSA &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and the Gleason score &le;6 (",
"    <a class=\"graphic graphic_table graphicRef81673 \" href=\"UTD.htm?3/33/3612\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Standard treatment options for these patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active surveillance, with serial monitoring and the initiation of definitive treatment if there is evidence of progression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H833697#H833697\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Active surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation therapy, which may be delivered from either an external beam source or by brachytherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H833704#H833704\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Radiation therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radical prostatectomy, which may be carried out either by an open or minimally invasive approach. Lymph node dissection is optional for those with very low risk and low risk disease. For patients managed with radical prostatectomy, the surgical pathology specimen may result in a change in staging that suggests additional postoperative therapy may improve the chance for cure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H833938#H833938\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Radical prostatectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized clinical trials that compare these three approaches in men with low-risk prostate cancer, and the choice of therapy depends upon an informed patient decision incorporating knowledge about the potential advantages and disadvantages associated with each approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H834319#H834319\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ablative techniques (cryotherapy, high-intensity ultrasound [HIFU]) have been advocated, but there are inadequate long term data to consider these as standard approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H832085#H832085\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Ablation therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43000?source=see_link\">",
"     \"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11494944\">",
"    <span class=\"h2\">",
"     Clinically localized, intermediate-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intermediate-risk, clinically localized prostate cancer can have more extensive tumor in the prostate (ie, involving more than one-half of one lobe of the prostate [T2b] or with bilateral disease [T2c] on initial examination or imaging), but without detectable extracapsular extension or seminal vesicle involvement (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ). In addition, patients with T1 or T2a disease also are classified as having intermediate risk disease based upon a serum PSA between 10 and 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or a biopsy Gleason score 7 (",
"    <a class=\"graphic graphic_table graphicRef81673 \" href=\"UTD.htm?3/33/3612\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Standard treatment options for intermediate risk patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy, which may be delivered by either an external beam source or brachytherapy. Because of the increased risk of recurrence or disseminated disease, androgen deprivation therapy (ADT) may be used as a component of a combined modality approach. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link&amp;anchor=H181128718#H181128718\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'Radiation therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radical prostatectomy with pelvic lymph node dissection, which may be carried out either by an open or minimally invasive approach. For patients managed with radical prostatectomy, the presence of adverse pathologic features in the surgical staging specimen may be an indication for adjuvant (postoperative) radiation therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link&amp;anchor=H181131068#H181131068\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'Radical prostatectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Active surveillance is not indicated in these patients, except for those with a limited life expectancy based upon age or comorbidity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H833697#H833697\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Active surveillance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11494951\">",
"    <span class=\"h2\">",
"     Clinically localized, high-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with high-risk, clinically localized prostate cancer have more extensive disease based upon the presence of presumed extracapsular extension on digital rectal examination (T3a) or are classified as being at high risk because of a serum PSA &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or a Gleason score of 8 to 10 (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81673 \" href=\"UTD.htm?3/33/3612\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Standard treatment options for these patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy using an external beam source. Long-term (two to three years) ADT is generally indicated as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link&amp;anchor=H181128718#H181128718\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'Radiation therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radical prostatectomy with extended pelvic lymph node dissection is an option for high-risk patients without fixation to adjacent",
"      <span class=\"nowrap\">",
"       organs/tissue.",
"      </span>",
"      For high-risk patients managed with radical prostatectomy, the presence of adverse pathologic features in the surgical staging specimen may be an indication for adjuvant (postoperative) radiation therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ADT for those with node positive disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H833938#H833938\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Radical prostatectomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link&amp;anchor=H181131068#H181131068\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'Radical prostatectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1120181\">",
"    <span class=\"h2\">",
"     Clinically locally advanced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose initial evaluation suggests locally advanced disease (T3b or T4) with seminal vesicle involvement, tumor fixation, or invasion of adjacent organs are classified as being very high risk for progression or recurrence. Imaging of the pelvis (CT, MRI) may be considered for those at significant risk of pelvic lymph node involvement.",
"   </p>",
"   <p>",
"    Treatment options for men with very high risk, locally advanced disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      External beam radiation therapy with long term ADT. In some cases, the external beam radiation therapy may be combined with brachytherapy to increase the radiation dose to the primary tumor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link\">",
"       \"External beam radiation therapy for localized prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radical prostatectomy combined with extended pelvic lymph node dissection may also be an option for very high risk patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link\">",
"       \"Radical prostatectomy for localized prostate cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In this setting, the serum PSA provides important information on whether or not all disease has been resected and whether further therapy is indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link&amp;anchor=H6#H6\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'Treatment approaches'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients in whom the serum PSA is undetectable following definitive surgery, careful monitoring is indicated including digital rectal examination and serum PSA every three to six months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link\">",
"       \"Follow-up surveillance during and after treatment for prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the PSA fails to fall to undetectable levels or if the PSA subsequently rises, patients are presumed to have residual or recurrent disease. Such patients should be evaluated for evidence of metastatic disease, and subsequent therapy is dictated by the results of that evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=see_link\">",
"       \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1120188\">",
"    <span class=\"h2\">",
"     Clinical lymph node involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lymph node involvement are classified as having stage IV (metastatic) disease in the AJCC",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    UICC staging system (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ). Patients with lymph node metastases diagnosed based upon clinical staging but without distant metastases are usually treated with definitive RT plus ADT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link\">",
"     \"External beam radiation therapy for localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11494965\">",
"    <span class=\"h2\">",
"     Disseminated metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to the management disseminated metastases (M1) and for a detectable or rising serum PSA following treatment in those who are not candidates for definitive locoregional therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other factors can affect the likelihood of subsequent relapse, although these are not been routinely incorporated into predictive tools.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Percentage of positive biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimate of tumor volume in the prostate needle biopsy can provide additional useful information [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. The best method to assess the volume of cancer in the prostate biopsy is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/9\">",
"     9",
"    </a>",
"    ], but this parameter can be quantified using the maximal percentage of a core involved with cancer, the percentage of cores that are positive, or the pathologist's estimate of the percentage of biopsy tissue containing cancer overall. The generic term \"percentage of positive biopsies\" is often applied to any of these quantitative measures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H14#H14\">",
"     \"Interpretation of prostate biopsy\", section on 'Estimated tumor volume'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The influence of prostate biopsy tumor volume on outcome was illustrated by a report of 960 surgically treated men, in which 80 percent of those in the intermediate-risk group (clinical stage T2b, biopsy Gleason grade 7, or preoperative serum PSA between 10 and 20",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    could be classified into two separate risk groups based upon the fraction of prostate biopsies that were found to contain cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with &gt;50 percent positive biopsies had an 11 percent likelihood of PSA control at four years.",
"     </li>",
"     <li>",
"      Patients with &lt;34 percent positive biopsies had an 86 percent likelihood of PSA control at four years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar refinement in prognostication was demonstrated for patients in the high-risk group. In contrast, the percentage of positive biopsies provided no additional prognostic value in patients at low risk for recurrence.",
"   </p>",
"   <p>",
"    Another report showed that men at low risk of recurrence with &gt;50 percent positive biopsies were significantly more likely to be pathologically upgraded at surgery from Gleason &le;6 to Gleason 7 tumors than those with fewer than 50 percent positive samples (59 versus 26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/5\">",
"     5",
"    </a>",
"    ]. These higher rates of pathologic upgrading translated into significantly lower five-year PSA failure-free survival rates (62 versus 92 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cancer volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with clinically localized prostate cancer, the calculated prostate cancer volume may permit further refinements in predicting the likelihood of organ-confined disease. The calculated prostate cancer volume takes into consideration the prostate gland volume (determined by transrectal ultrasound), serum PSA concentration, and biopsy Gleason score [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H14#H14\">",
"     \"Interpretation of prostate biopsy\", section on 'Estimated tumor volume'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 1773 men with clinically localized prostate cancer undergoing either radical prostatectomy or conformal radiation therapy at two different institutions, a calculated volume &gt;4.0 cm",
"    <sup>",
"     3",
"    </sup>",
"    identified patients with a shorter time to PSA failure than was predicted by their T stage (clinical T1c or T2 for patients treated by radiation, and pathological T2 stage for those undergoing radical prostatectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In practice, precise estimates of cancer volume are difficult to obtain prior to treatment because of limitations in current imaging modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Perineural invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perineural invasion (PNI) in the biopsy specimen is a predictor of the presence of extraprostatic extension at the time of prostatectomy. As an example, in one series the likelihood of a positive margin was higher in men with perineural invasion compared with those without invasion (25 versus 17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H15#H15\">",
"     \"Interpretation of prostate biopsy\", section on 'Perineural invasion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether perineural invasion affects prognosis after definitive therapy is unclear. In two large contemporary series of men with clinically localized disease, one using radiation therapy and the other surgery, the presence of perineural invasion in the biopsy specimen was an independent predictor of biochemical relapse-free survival in men with low-risk disease (serum PSA &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    Gleason score &le;6, and clinical T1c or T2a disease), but provided no additional prognostic value for men with intermediate- or high-risk disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, no adverse influence of perineural invasion on outcome was found in two other series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This was illustrated by a series of 364 men, including 287 with perineural invasion, who underwent radical prostatectomy over a four-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/17\">",
"     17",
"    </a>",
"    ]. Although perineural invasion was associated with multiple adverse pathologic features (larger tumor volume, higher grade disease, increased incidence of extraprostatic extension and seminal vesicle invasion), it was not an independent predictor of PSA recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Disseminated cancer cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although disseminated cancer cells in the systemic circulation and in the bone marrow can be detected in patients with early stage prostate cancer, this technique has not been shown to be useful as a prognostic tool. The use of circulating cancer cells as a prognostic tool in patients with advanced prostate cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link&amp;anchor=H501733343#H501733343\">",
"     \"Overview of the treatment of disseminated prostate cancer\", section on 'Prognostic biomarkers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link&amp;anchor=H501733350#H501733350\">",
"     \"Overview of the treatment of disseminated prostate cancer\", section on 'Circulating tumor cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREDICTIVE TOOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of combinations of pretreatment clinical and pathologic factors (eg, serum PSA level, Gleason score, clinical T stage) allow a more reliable prediction of pathologic stage and treatment outcome. These parameters have been integrated into anatomic stage prognostic groups in the seventh (2010) TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Efforts to improve the prognostic accuracy of these parameters include the incorporation of cellular and biologic data [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/18\">",
"     18",
"    </a>",
"    ] and the use of gene expression data [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/19\">",
"     19",
"    </a>",
"    ]. However, such improvements in accuracy must be balanced against the complexity and cost added by their use and the limitations in their ability to affect clinical decision-making [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of these predictive tools require validation in an external data set, and all are limited in their applicability to the populations from which they were developed. Furthermore, changes in either population over time (eg, stage migration) or treatment approaches may limit their subsequent utility.",
"   </p>",
"   <p>",
"    A number of different approaches have been used to integrate this information [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The most important of these are the use of nomograms and risk tables. Nomograms appear to offer advantages in terms of increased accuracy, whereas risk tables may offer increased simplicity in their application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nomograms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple nomograms are available for use in men with newly diagnosed prostate cancer or following initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9704/abstract/21\">",
"     21",
"    </a>",
"    ]. These nomograms can incorporate demographic data such as age, Gleason score, clinical stage, and treatment plans to help estimate the risk of recurrence or progression in a variety of clinical scenarios.",
"   </p>",
"   <p>",
"    A number of validated nomograms are accessible online:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (",
"      <a class=\"external\" href=\"file://www.mskcc.org/mskcc/html/10088.cfm\">",
"       www.mskcc.org/mskcc/html/10088.cfm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (",
"      <a class=\"external\" href=\"file://www.nomogram.org/\">",
"       www.nomogram.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (",
"      <a class=\"external\" href=\"file://www.palpable-prostate.blogspot.com/2007/02/prosate-cancer-calculators.html\">",
"       www.palpable-prostate.blogspot.com/2007/02/prosate-cancer-calculators.html",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=see_link\">",
"       \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of men with newly diagnosed prostate cancer depends upon a pretreatment assessment of the risk of locoregional recurrence or disseminated disease. Key factors in this assessment include clinical staging of the extent of disease (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ), the pretreatment serum PSA, and the Gleason score in the pretreatment biopsy. Based upon this information, and the results of additional studies as may be indicated, patients are divided into several categories, which provides the basis for treatment decisions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk, clinically localized prostate cancer &ndash; no apparent tumor in the prostate (ie, diagnosis based upon a biopsy only, with no abnormal findings on imaging or palpation) or limited disease in one lobe of the prostate gland, a serum PSA &lt;10",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      and the Gleason score &le;6. (See",
"      <a class=\"local\" href=\"#H11494937\">",
"       'Clinically localized, low risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intermediate-risk, clinically localized prostate cancer &ndash; tumor in the prostate involves more than one-half of one lobe of the prostate [T2b] or with bilateral disease [T2c] but without detectable extracapsular extension or seminal vesicle involvement. In addition, patients with T1 or T2a disease are classified as having intermediate risk disease based upon a serum PSA between 10 and 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or a biopsy Gleason score 7. (See",
"      <a class=\"local\" href=\"#H11494944\">",
"       'Clinically localized, intermediate-risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-risk, clinically localized prostate cancer &ndash; tumor with extracapsular extension (T3a) or a serum PSA &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or a biopsy Gleason score of 8 to 10. (See",
"      <a class=\"local\" href=\"#H11494951\">",
"       'Clinically localized, high-risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Locally advanced (very high risk) prostate cancer &ndash; seminal vesicle involvement (T3b), tumor fixation (T4), or invasion of adjacent organs (T4). (See",
"      <a class=\"local\" href=\"#H1120181\">",
"       'Clinically locally advanced'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymph node involvement &ndash; Patients with lymph node involvement are classified as having stage IV (metastatic) disease. (See",
"      <a class=\"local\" href=\"#H1120188\">",
"       'Clinical lymph node involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated disease &ndash; Patients with disseminated metastases (M1) are classified as having stage IV (metastatic) disease. (See",
"      <a class=\"local\" href=\"#H11494965\">",
"       'Disseminated metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of predictive tools have been developed, to assist the patient and clinician in choosing the optimal therapy. These include both nomograms, which may be more accurate, and risk tables, which have the potential advantage of simplicity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Nomograms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/2\">",
"      Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177:2106.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/4\">",
"      D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/5\">",
"      Lee AK, Schultz D, Renshaw AA, et al. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys 2001; 49:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/6\">",
"      D'Amico AV, Schultz D, Silver B, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2001; 49:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/7\">",
"      Grossfeld GD, Latini DM, Lubeck DP, et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology 2002; 59:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/8\">",
"      D'Amico AV, Keshaviah A, Manola J, et al. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/9\">",
"      Freedland SJ, Aronson WJ, Csathy GS, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology 2003; 61:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/10\">",
"      Greene KL, Elkin EP, Karapetian A, et al. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE. J Urol 2006; 175:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/11\">",
"      D'Amico AV, Whittington R, Malkowicz SB, et al. Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J Clin Oncol 1998; 16:3094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/12\">",
"      Lee SH, Park KK, Choi KH, et al. Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging. World J Urol 2010; 28:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/13\">",
"      Chabanova E, Balslev I, Logager V, et al. Prostate cancer: 1.5 T endo-coil dynamic contrast-enhanced MRI and MR spectroscopy--correlation with prostate biopsy and prostatectomy histopathological data. Eur J Radiol 2011; 80:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/14\">",
"      D'Amico AV, Wu Y, Chen MH, et al. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol 2001; 165:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/15\">",
"      Anderson PR, Hanlon AL, Patchefsky A, et al. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA &lt;10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 1998; 41:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/16\">",
"      O'Malley KJ, Pound CR, Walsh PC, et al. Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology 2002; 59:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/17\">",
"      Ng JC, Koch MO, Daggy JK, Cheng L. Perineural invasion in radical prostatectomy specimens: lack of prognostic significance. J Urol 2004; 172:2249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/18\">",
"      Donovan MJ, Hamann S, Clayton M, et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 2008; 26:3923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/19\">",
"      Cheville JC, Karnes RJ, Therneau TM, et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 2008; 26:3930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/20\">",
"      Klein EA, Stephenson AJ, Raghavan D, Dreicer R. Systems pathology and predicting outcome after radical prostatectomy. J Clin Oncol 2008; 26:3916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/21\">",
"      Shariat SF, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 2008; 14:4400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9704/abstract/22\">",
"      Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008; 113:3075.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6943 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9704=[""].join("\n");
var outline_f9_30_9704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11494930\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4280895\">",
"      Clinically localized, very low risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11494937\">",
"      Clinically localized, low risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11494944\">",
"      Clinically localized, intermediate-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11494951\">",
"      Clinically localized, high-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1120181\">",
"      Clinically locally advanced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1120188\">",
"      Clinical lymph node involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11494965\">",
"      Disseminated metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Percentage of positive biopsies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cancer volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Perineural invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Disseminated cancer cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREDICTIVE TOOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nomograms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6943|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/59/15281\" title=\"figure 1\">",
"      Pathologic staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41277\" title=\"table 1\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10941\" title=\"table 2\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/33/3612\" title=\"table 3\">",
"      Pretreat risk stratify prost CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43000?source=related_link\">",
"      Cryotherapy and other ablative techniques for the initial treatment of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23527?source=related_link\">",
"      Initial staging and evaluation of men with newly diagnosed prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=related_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=related_link\">",
"      Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=related_link\">",
"      Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_30_9705="Etiology, clinical features, and evaluation of chronic mitral regurgitation";
var content_f9_30_9705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/30/9705/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9705/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/30/9705/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9705/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9705/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/30/9705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9705/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/30/9705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral regurgitation (MR) is a common valvular disorder that can arise from abnormalities of any part of the mitral valve apparatus. These include the valve leaflets, annulus, chordae tendineae, and papillary muscles (",
"    <a class=\"graphic graphic_table graphicRef64974 \" href=\"UTD.htm?18/20/18765\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79932 \" href=\"UTD.htm?5/22/5476\">",
"     figure 1",
"    </a>",
"    ). The left atrial wall and ventricular myocardium adjacent to the papillary muscles are also integrally involved with mitral valve function.",
"   </p>",
"   <p>",
"    The widespread use of color Doppler echocardiography, a sensitive technique for detecting valvular regurgitation, has increased the recognition of this lesion, even in healthy subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of MR varies inversely with severity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trivial amount of MR is detectable with sensitive Doppler techniques in up to 70 percent of healthy adults; this is often termed \"physiologic\" mitral regurgitation.",
"     </li>",
"     <li>",
"      In the Framingham Heart Study, a population-based cohort, MR of &ge;mild severity on color Doppler echocardiography was present in 19 percent of men and women [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review of 3486 subjects in the Strong Heart Study, moderate or severe MR was found in 1.9 and 0.2 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The etiology and clinical manifestations of chronic MR will be reviewed here. Issues related to acute MR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral regurgitation may be due to a primary abnormality of the valve apparatus or may be secondary to another cardiac disease. The causes of primary MR include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitral valve prolapse is the most common cause of primary MR in developed countries and is also called \"degenerative\" or myxomatous mitral valve disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link&amp;anchor=H2#H2\">",
"       \"Nonarrhythmic complications of mitral valve prolapse\", section on 'Mitral regurgitation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infective endocarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link&amp;anchor=H3#H3\">",
"       \"Complications and outcome of infective endocarditis\", section on 'Cardiac complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trauma, which can cause ruptured chordae and acute MR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"       \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rheumatic heart disease is uncommon in developed countries but continues to constitute a significant burden in the rest of the world. Rheumatic mitral valve disease is more frequent in women than men and disease detection is higher by echocardiography compared to clinical examination. This was demonstrated in an echocardiographic screening study from Cambodia and Mozambique in which the mitral valve was involved in 87 and 98 percent of detected cases of rheumatic heart disease; all were due to MR as there were no cases of mitral stenosis in this young population (ages 6 to 17 years old) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"      </a>",
"      .) Although rheumatic valve disease often results in MR in the first two decades of life, mitral stenosis and mixed mitral stenosis plus MR are more often seen in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Rheumatic disease is an uncommon cause of significant MR in adults in developed countries.",
"     </li>",
"     <li>",
"      Anorectic drug combinations that are no longer available and prolonged use of certain other drugs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      , pergolide, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      , which may induce MR by a mechanism similar to that with anorectic drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1528?source=see_link\">",
"       \"Valvular heart disease induced by drugs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link&amp;anchor=H14#H14\">",
"       \"Pharmacologic treatment of Parkinson disease\", section on 'Dopamine agonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital due, for example, to a valve cleft.",
"     </li>",
"     <li>",
"      Mitral annular calcification is a common finding in older adults that is often associated with mild to moderate MR and is less commonly associated with severe MR. The prevalence of mitral annular calcification increases with age. There also typically are mild calcific changes of the valve leaflets associated with aging [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37801?source=see_link\">",
"       \"Mitral annular calcification\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The secondary (functional) causes of MR include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic heart disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"       \"Ischemic mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Left ventricular systolic dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"       \"Functional mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mitral valve prolapse, infective endocarditis, trauma, and rupture of a papillary muscle in the setting of an acute myocardial infarction can lead to a flail or partial flail mitral leaflet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the developed world, rheumatic heart disease is now uncommon and the major etiologies of MR are mitral valve prolapse and coronary heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nature and severity of the symptoms associated with chronic MR are related to the severity of MR, its rate of progression, the pulmonary artery pressure, arrhythmias (eg, atrial fibrillation), and associated cardiac disease. Patients with isolated mild to moderate MR are asymptomatic, since there is little volume overload of the ventricle and cardiac hemodynamics and forward cardiac output remain normal. Even with severe MR, most patients remain asymptomatic until there is left ventricular failure, pulmonary hypertension, or the onset of atrial fibrillation.",
"   </p>",
"   <p>",
"    The most common symptoms, when present, are exertional dyspnea and fatigue due to the combination of a decreased forward (ie, effective) cardiac output, an increase in left atrial pressure due to backflow across the mitral valve, and pulmonary artery hypertension. Another common clinical presentation is intermittent or persistent atrial fibrillation.",
"   </p>",
"   <p>",
"    Because of the importance of identifying the transition from asymptomatic to symptomatic MR in determining the timing of mitral valve surgery, a careful history is important to establish a good estimate of baseline exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with more severe disease and left ventricular enlargement eventually progress to symptomatic heart failure with pulmonary congestion and edema. At this stage of left ventricular dilatation, the myocardial dysfunction is often irreversible due to the long standing MR. In some cases, irreversible left ventricular systolic dysfunction occurs in the absence of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36901?source=see_link\">",
"     \"Pathophysiology and stages of chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other symptoms such as thromboembolism, hemoptysis, and right-sided heart failure do occur, but are less common than with mitral stenosis. However, there is a high risk for infective endocarditis in patients with an abnormal mitral valve and moderate to severe MR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In chronic MR, the arterial pulse may be reduced in volume, but is usually brisk in upstroke, reflecting the increased left ventricular ejection rate and normal ejection fraction. Since there is a rapid reduction in the volume of forward flow late in systole and therefore a decrease in ejection time, the arterial pulse falls off rapidly, giving the impression of a bounding pulse, similar to that seen with aortic regurgitation. However, the pulse pressure is normal with MR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link\">",
"     \"Examination of the arterial pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enlargement of the left ventricle results in a leftward displacement of the apical impulse; it is usually brisk or hyperdynamic. When the MR is severe or when there has been an acute exacerbation of the regurgitation as a result of a chordal rupture, a thrill and an S3 may be palpable. Signs of right-sided congestive heart failure are typically absent unless there is associated mitral stenosis or the MR is of long standing and is very severe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CARDIAC AUSCULTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Heart sounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a murmur, chronic MR can produce changes in the heart sounds (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S1 is diminished, reflecting failure of the mitral leaflets to close properly.",
"     </li>",
"     <li>",
"      Wide splitting of S2 is common because the decrease in left ventricular ejection time results in an early A2. Furthermore, if pulmonary artery hypertension is present, P2 will be increased and delayed, further widening the splitting of S2.",
"     </li>",
"     <li>",
"      The augmented flow rate across the mitral valve orifice into a dilated left ventricle produces an S3 gallop, which becomes particularly prominent if left ventricular failure occurs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Murmurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The murmur of MR is systolic but its timing, duration, quality, intensity, location, and radiation are variable and depend upon the etiology and component of the mitral apparatus that is diseased. In most cases, the murmur is holosystolic, commencing immediately after S1 and continuing up to and sometime beyond and obscuring A2, a result of the persistent pressure gradient between the left ventricle and atrium after aortic valve closure.",
"   </p>",
"   <p>",
"    The murmur is heard best over the apex, radiating to the axilla and when very loud may often radiate to the back. It is most often blowing and high pitched in quality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a variable correlation between the MR murmur grade and regurgitant severity with primary mitral valve disease. A loud murmur associated with a thrill (grade 4 or greater) has a specificity of 91 percent for severe MR, but a sensitivity of only 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/11\">",
"     11",
"    </a>",
"    ]. Conversely, severe MR is rarely present with a grade 1-2 murmur. However, there is a wide range of MR severity with a grade 3 murmur (which is common) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The loudness of the murmur correlates even less well with severity in secondary (functional) MR. In addition, among patients with acute MR due to ischemia, moderate to severe MR is often silent or associated with only a soft murmur due to equalization of left ventricular and left atrial pressures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\", section on 'Silent MR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the classic holosystolic murmur, other types of murmurs can be heard in chronic MR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the posterior leaflet is predominantly involved (due to prolapse or chordal rupture), the murmur may radiate anteriorly toward the sternum and is heard well at the base. This type of murmur is often confused with aortic stenosis but does not radiate to the carotid arteries.",
"     </li>",
"     <li>",
"      When the anterior leaflet is predominantly involved (due to prolapse or chordal rupture), the murmur is often loud, radiates to the back, and may be heard on the top of the head as a result of the excellent sound transmission along the vertebral column.",
"     </li>",
"     <li>",
"      A mid to late systolic murmur, harsh in quality, is often heard when the MR is due to prolapse or papillary muscle displacement (previously known as papillary muscle dysfunction). When the murmur is confined to late systole, the degree of MR is usually only mild to moderate, even if the murmur is loud. S1 is intact in this setting, since the initial closure of the mitral leaflets is normal. The murmur of papillary muscle displacement is variable and becomes louder and longer when there is an acute ischemic episode.",
"     </li>",
"     <li>",
"      Infrequently, the large diastolic volume across the mitral valve with severe MR produces an early diastolic murmur (",
"      <a class=\"graphic graphic_movie graphicRef56783 \" href=\"UTD.htm?15/24/15744\">",
"       movie 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When the cause is mitral valve prolapse, a mid systolic click (correlating with the maximal prolapse and tension on the chordae) may be heard and the murmur may start in mid to late systole (",
"      <a class=\"graphic graphic_movie graphicRef57858 \" href=\"UTD.htm?7/55/8051\">",
"       movie 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link&amp;anchor=H28356962#H28356962\">",
"       \"Definition and diagnosis of mitral valve prolapse\", section on 'Physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart failure and the volume and geometry of the left ventricle can affect the timing, intensity, and quality of the MR murmur. In patients with MR due to dilatation of the valvular annulus, the murmur often diminishes in intensity or disappears as the heart failure is treated and left ventricular function improves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect of diagnostic maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the murmur of MR may be variable, it is important to distinguish it from the murmurs associated with other valvular lesions. The use of certain maneuvers may be helpful in this regard. However, interpretation of changes in a murmur with maneuvers is difficult and may not be reproducible, and the most accurate method for determining the cause of a systolic murmur is echocardiography.",
"   </p>",
"   <p>",
"    As a result, pharmacologic agents are not used to evaluate murmurs in usual clinical practice. Nevertheless, the expected changes illustrate the underlying physiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=see_link\">",
"     \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The murmur of MR has the following characteristics (",
"    <a class=\"graphic graphic_figure graphicRef61744 \" href=\"UTD.htm?16/62/17391\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69748 \" href=\"UTD.htm?25/56/26508\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is little respiratory variation.",
"     </li>",
"     <li>",
"      The murmur may become louder when left ventricular volume increases (heart failure or occasionally with an increase in venous return as occurs with leg raising or lying down) or when afterload increases (squatting or isometric hand grip).",
"     </li>",
"     <li>",
"      There is a decrease in intensity when venous return is reduced due to standing or the Valsalva maneuver.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These maneuvers can also produce changes in patients with mitral valve prolapse. Those maneuvers that decrease venous return and reduce the left ventricular volume cause the systolic click to occur earlier (move toward S1) and the murmur to be of longer duration (although it is often fainter). On the other hand, those maneuvers that increase venous return or afterload cause the click to occur later (move toward S2) and the murmur to be abbreviated (",
"    <a class=\"graphic graphic_table graphicRef69748 \" href=\"UTD.htm?25/56/26508\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link&amp;anchor=H28356962#H28356962\">",
"     \"Definition and diagnosis of mitral valve prolapse\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of patients with valvular heart disease included recommendations for the use of echocardiography in patients with murmurs (",
"    <a class=\"graphic graphic_table graphicRef50108 \" href=\"UTD.htm?36/4/36939\">",
"     table 3",
"    </a>",
"    ), for the role of echocardiography in patients with MR (",
"    <a class=\"graphic graphic_table graphicRef68474 \" href=\"UTD.htm?3/34/3628\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63907 \" href=\"UTD.htm?30/15/30971\">",
"     table 5",
"    </a>",
"    ), and for coronary angiography in patients with chronic MR (",
"    <a class=\"graphic graphic_table graphicRef55552 \" href=\"UTD.htm?37/11/38075\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram in chronic MR most often reflects the hemodynamic burden placed on the left atrium, which can lead to left atrial enlargement, similar to that seen in mitral stenosis. The P wave broadens (&gt;0.12 sec in lead II), becomes increased in amplitude, has a notching, and has a significant negative component in V1 (called \"P-mitrale\"). Other changes are less specific:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When there is left ventricular hypertrophy, the QRS amplitude increases, especially in the precordial leads and lead aVL. ST-T wave abnormalities (ST segment is depressed and the T wave is inverted) are also common in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"       \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When pulmonary artery hypertension is present, there may be evidence of right ventricular hypertrophy, which includes a tall R wave in V1 or V2 with",
"      <span class=\"nowrap\">",
"       R/S",
"      </span>",
"      ratio &gt;1. Although right ventricular hypertrophy tends to shift the axis to the right, this may not occur in patients who also have left ventricular hypertrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common finding on the chest radiograph is cardiomegaly, resulting from enlargement of the left ventricle and the left atrium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75174 \" href=\"UTD.htm?11/59/12213\">",
"     image 1",
"    </a>",
"    ). However, left ventricular size does not correlate with the severity of MR, nor does left atrial size correlate with the elevation of left atrial pressure.",
"   </p>",
"   <p>",
"    Left ventricular enlargement causes the cardiac silhouette to be displaced towards the left chest wall and the chamber becomes globular. Enlargement of the left atrium results in a straightening of the left heart border with the appearance of a double density and elevation of the left main stem bronchus.",
"   </p>",
"   <p>",
"    The right ventricle is usually normal in size, unless there is pulmonary hypertension. Similarly, the lung fields are usually clear unless congestive heart failure is present. Calcification of the mitral valve annulus may be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is essential for establishing the etiology and hemodynamic consequences of MR (",
"    <a class=\"graphic graphic_table graphicRef68474 \" href=\"UTD.htm?3/34/3628\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ]. Other important echocardiographic features are left atrial size, left ventricle size and systolic function, and pulmonary artery pressures. Left atrial size is usually increased. Left ventricular size and systolic function are normal early in the disease course but progressive ventricular dilation and a decline in ejection fraction occur with chronic severe MR. Serial studies permit measurement of changes in ventricular dimensions or left ventricular ejection fraction. Pulmonary artery pressures also can be noninvasively estimated using Doppler echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transthoracic echocardiography (TTE) is diagnostic in most cases, but if image quality is suboptimal, transesophageal echocardiography (TEE) is recommended (",
"    <a class=\"graphic graphic_table graphicRef63907 \" href=\"UTD.htm?30/15/30971\">",
"     table 5",
"    </a>",
"    ). One study of 248 patients found that, when compared to surgical diagnosis, the accuracy of TEE was high: 99 percent for etiology and mechanism, presence of vegetations, and prolapsed or flail segment, and 88 percent for ruptured chordae; diagnostic accuracy was higher for TEE compared to TTE [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42040?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of mitral valve disease\"",
"    </a>",
"    .) Three-dimensional TTE and TEE may be particularly helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=see_link&amp;anchor=H11#H11\">",
"     \"Three-dimensional echocardiography\", section on 'Mitral valve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Severity of mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler and color flow Doppler can be used to measure the severity of MR (",
"    <a class=\"graphic graphic_movie graphicRef63107 \" href=\"UTD.htm?8/37/8784\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef75955 \" href=\"UTD.htm?16/31/16884\">",
"     movie 4",
"    </a>",
"    ). The simplest approach is measurement of the narrowest segment of the jet, or vena contracta, on color flow imaging. Mitral regurgitant severity can be measured more precisely, when clinically indicated, by calculation of the regurgitant volume, regurgitant fraction, and regurgitant orifice area using standard Doppler approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the 2003 American Society of Echocardiography guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/15\">",
"     15",
"    </a>",
"    ], the following findings are consistent with severe MR (",
"    <a class=\"graphic graphic_table graphicRef77111 \" href=\"UTD.htm?34/46/35564\">",
"     table 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vena contracta width &ge;0.7 cm",
"     </li>",
"     <li>",
"      Regurgitant orifice area &ge;0.40 cm",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Regurgitant volume &ge;60 mL",
"     </li>",
"     <li>",
"      Regurgitant fraction &ge;50 percent",
"     </li>",
"     <li>",
"      Regurgitant jet area &gt;40 percent of left atrial area, but this is less reproducible and less often used",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many also include systolic reversal of flow in a pulmonary vein but systolic flow reversal may not be present in all four pulmonary veins with an eccentric jet. In addition, normal systolic flow in the pulmonary veins occurs due to atrial relaxation after normal atrial contraction; thus, in atrial fibrillation, systolic blunting or flow reversal may be seen even in the absence of significant mitral regurgitation.",
"   </p>",
"   <p>",
"    These values are based on an average adult size and may need to be adjusted for body size in small or large patients; however, there is no specific formula for making this adjustment. The diagnosis of severe MR is most secure when more than one of these findings is present.",
"   </p>",
"   <p>",
"    In addition, assessment of the overall severity of MR should take into account the cause and acuteness of the lesion, left ventricular size and systolic function, left atrial size, and pulmonary artery systolic pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of echo-Doppler grading, severe chronic MR does",
"    <strong>",
"     NOT",
"    </strong>",
"    exist (with rare exceptions) without clear evidence of left atrial or left ventricular enlargement. If the left ventricular end-diastolic dimension (by echocardiography) is less than 60 mm (approximately 35",
"    <span class=\"nowrap\">",
"     mm/m2),",
"    </span>",
"    the diagnosis of severe chronic MR should be seriously questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/16\">",
"     16",
"    </a>",
"    ]. Left atrial size may reflect the \"history\" (severity and duration) of chronic MR [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36901?source=see_link\">",
"     \"Pathophysiology and stages of chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cause of mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two dimensional imaging allows accurate determination of the cause of MR. If transthoracic echocardiography is nondiagnostic, the next step is transesophageal echocardiography.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With mitral valve prolapse, there is posterior movement of the leaflets (hammocking) into the left atrium during systole (",
"      <a class=\"graphic graphic_movie graphicRef65137 \" href=\"UTD.htm?31/23/32115\">",
"       movie 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef76601 \" href=\"UTD.htm?8/32/8707\">",
"       movie 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef57557 \" href=\"UTD.htm?23/5/23646\">",
"       movie 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef52330 \" href=\"UTD.htm?15/50/16162\">",
"       movie 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef78402 \" href=\"UTD.htm?20/12/20672\">",
"       movie 9",
"      </a>",
"      ). This generally correlates with the click, which is heard at variable times during systole. Either one or both leaflets may prolapse to variable degrees. In addition, the leaflets are thickened and redundant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link&amp;anchor=H28357003#H28357003\">",
"       \"Definition and diagnosis of mitral valve prolapse\", section on 'Echocardiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With endocarditis, vegetations are present, typically on the atrial side of the mitral valve leaflets. TEE is more sensitive than TTE for detection of vegetations and should be considered when endocarditis is suspected (",
"      <a class=\"graphic graphic_movie graphicRef58456 \" href=\"UTD.htm?17/39/18035\">",
"       movie 10",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef53844 \" href=\"UTD.htm?1/25/1427\">",
"       movie 11",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link&amp;anchor=H14#H14\">",
"       \"Diagnostic approach to infective endocarditis\", section on 'Echocardiography'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link\">",
"       \"Role of echocardiography in infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When a perforated mitral valve leaflet is present, an MR jet can be seen passing through the leaflet (",
"      <a class=\"graphic graphic_movie graphicRef55066 \" href=\"UTD.htm?15/52/16194\">",
"       movie 12",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef79920 \" href=\"UTD.htm?2/1/2064\">",
"       movie 13",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef58795 \" href=\"UTD.htm?36/9/37010\">",
"       movie 14",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When a chordal or papillary muscle rupture is present, the movement of the leaflets is markedly exaggerated and the ruptured chord or papillary muscle is seen in the left atrium in systole (",
"      <a class=\"graphic graphic_movie graphicRef64363 \" href=\"UTD.htm?16/48/17154\">",
"       movie 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef60709 \" href=\"UTD.htm?12/21/12628\">",
"       movie 16",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef61846 \" href=\"UTD.htm?17/43/18099\">",
"       movie 17",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"       \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With MR due to rheumatic heart disease, there is significant thickening of the leaflets and some evidence of commissural fusion or chordal shortening",
"     </li>",
"     <li>",
"      Secondary (functional) MR due to left ventricular dilation and systolic dysfunction is characterized by failure of the mitral leaflets to close completely and a dilated mitral valve annulus. Ischemic MR, a form of secondary MR, is characterized by restricted leaflet motion, particularly of the posterior leaflet, resulting in inadequate apposition of the leaflets, often called \"tenting\" or \"tethering\" of the leaflets (",
"      <a class=\"graphic graphic_movie graphicRef52748 \" href=\"UTD.htm?24/60/25539\">",
"       movie 18",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef73594 \" href=\"UTD.htm?28/11/28850\">",
"       movie 19",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef54431 \" href=\"UTD.htm?33/59/34740\">",
"       movie 20",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"       \"Functional mitral regurgitation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"       \"Ischemic mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance (CMR) can be useful in selected patients with MR, although not recommended for routine diagnosis or monitoring due to cost considerations. When echocardiographic measures of MR severity or left ventricular function are inadequate or borderline in the setting of LV dilation, or when there is a discrepancy between clinical findings and echocardiography, CMR assessment of MR severity may be helpful.",
"   </p>",
"   <p>",
"    CMR enables quantitation of the severity of MR based on calculating the regurgitant volume as the difference between left ventricular stroke volume and ascending aortic forward flow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/18\">",
"     18",
"    </a>",
"    ]. Alternatively, MR may be quantified by CMR planimetry of the regurgitant orifice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/19\">",
"     19",
"    </a>",
"    ]. CMR also enables highly detailed and accurate quantitation of left ventricular volumes and ejection fraction when these data are needed for clinical decision making [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive cardiac catheterization for measurement of intracardiac pressures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular angiography is rarely needed for the evaluation of chronic MR. The major indications for cardiac catheterization are for definition of coronary anatomy when patients are being considered for a mechanical intervention and when TTE and TEE do not provide diagnostic information or the findings are discrepant from the clinical features (",
"    <a class=\"graphic graphic_table graphicRef55552 \" href=\"UTD.htm?37/11/38075\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/10\">",
"     10",
"    </a>",
"    ]. As mentioned previously, CMR should also be considered in this situation.",
"   </p>",
"   <p>",
"    In patients in the intensive care unit with a right heart catheter in place, pressure recordings from the left atrium (or pulmonary capillary wedge position) may demonstrate a significant \"cv\" wave from the regurgitant blood flow into the left atrium (",
"    <a class=\"graphic graphic_waveform graphicRef74418 \" href=\"UTD.htm?13/4/13376\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef64953 \" href=\"UTD.htm?36/23/37234\">",
"     waveform 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients undergoing cardiac catheterization for other indications, left ventricular angiography may establish the presence and severity of MR. The diagnostic finding is opacification of the left atrium during systole. The rapidity and density of opacification of the left atrium provides a semiquantitative index of MR severity. The angiogram can also provide a measure left atrial and ventricular dimensions and left ventricular function.",
"   </p>",
"   <p>",
"    In contrast to its occasional utility in chronic MR, contrast angiography of the left ventricle is generally avoided at the time of catheterization in patients with acute MR because of the contrast load in an already compromised patient, (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\", section on 'Cardiac catheterization'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Coronary angiography prior to mitral valve surgery is recommended in patients with chronic MR who have or are suspected to have coronary disease (and who may have ischemic MR) and those at risk for coronary disease (",
"    <a class=\"graphic graphic_table graphicRef66360 \" href=\"UTD.htm?29/4/29772\">",
"     table 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9705/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\", section on 'Predicting coronary disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SERIAL MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the initial evaluation, serial monitoring with TTE is warranted in patients with chronic MR. The goals of TTE monitoring are to assess changes in clinical status by history and physical examination and to assess changes in left ventricular cavity size and systolic function, which can occur in the absence of symptoms.",
"   </p>",
"   <p>",
"    The recommendations for serial monitoring, which vary with the severity of MR, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Serial monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=see_link\">",
"       \"Patient information: Mitral regurgitation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=see_link\">",
"       \"Patient information: Mitral regurgitation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25853164\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary valve abnormalities that cause mitral regurgitation (MR) include mitral valve prolapse, infective endocarditis, trauma, rheumatic heart disease, certain drugs, and cleft mitral valve. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of secondary (functional) MR include ischemic heart disease, other types of left ventricular systolic dysfunction, and hypertrophic cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with severe MR are asymptomatic. When symptoms develop they include exertional dyspnea and fatigue. Another common clinical presentation is intermittent or persistent atrial fibrillation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with chronic MR, the arterial pulse is usually brisk and the apical impulse is usually hyperdynamic. The murmur of MR is usually holosystolic and blowing in quality. When MR is severe or when there has been an acute exacerbation of the regurgitation as a result of chordal rupture, a thrill and an S3 may be palpable. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography is essential for establishing the etiology and hemodynamic consequences of MR (",
"      <a class=\"graphic graphic_table graphicRef68474 \" href=\"UTD.htm?3/34/3628\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Echocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Criteria for severe MR include vena contracta width &ge;0.7 cm, regurgitant orifice area &ge;0.40 cm",
"      <sup>",
"       2",
"      </sup>",
"      , regurgitant volume &ge;60 mL, regurgitant fraction &ge;50 percent, and regurgitant jet area &gt;40 percent of left atrial area. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Severity of mitral regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regardless of echo-Doppler grading, severe chronic MR does not exist (with rare exceptions) without clear evidence of left atrial or left ventricular enlargement. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Severity of mitral regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the cause of MR cannot be identified by transthoracic echocardiography, the cause can generally be determined by transesophageal echocardiography. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Echocardiogram'",
"      </a>",
"      above.) Three-dimensional echocardiography may be particularly beneficial for defining valve morphology.",
"     </li>",
"     <li>",
"      Cardiovascular magnetic resonance (CMR) is not recommended for routine diagnosis of MR. When echocardiographic measures of MR severity or left ventricular function are inadequate or borderline in the setting of left ventricular dilation, or when there is a discrepancy between clinical findings and echocardiography, CMR assessment of MR severity at an experienced center may be helpful. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cardiovascular magnetic resonance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major indications for cardiac catheterization in a patient with MR are for definition of coronary anatomy when patients are being considered for an intervention and when echocardiography does not provide diagnostic information or the findings are discrepant from the clinical features (",
"      <a class=\"graphic graphic_table graphicRef55552 \" href=\"UTD.htm?37/11/38075\">",
"       table 6",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Cardiac catheterization'",
"      </a>",
"      above). CMR should also be considered for the latter.",
"     </li>",
"     <li>",
"      Recommendations for serial transthoracic echocardiographic monitoring, which vary with the severity of MR, are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of the management of chronic mitral regurgitation\", section on 'Serial monitoring'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/1\">",
"      Jones EC, Devereux RB, Roman MJ, et al. Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study). Am J Cardiol 2001; 87:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/2\">",
"      Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999; 83:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/3\">",
"      Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007; 357:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/4\">",
"      Marcus RH, Sareli P, Pocock WA, Barlow JB. The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann Intern Med 1994; 120:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/5\">",
"      Chockalingam A, Gnanavelu G, Elangovan S, Chockalingam V. Clinical spectrum of chronic rheumatic heart disease in India. J Heart Valve Dis 2003; 12:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/6\">",
"      Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992; 117:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/7\">",
"      Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/8\">",
"      Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005; 353:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/9\">",
"      Aronow WS, Kronzon I. Correlation of prevalence and severity of mitral regurgitation and mitral stenosis determined by Doppler echocardiography with physical signs of mitral regurgitation and mitral stenosis in 100 patients aged 62 to 100 years with mitral anular calcium. Am J Cardiol 1987; 60:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/10\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/11\">",
"      Desjardins VA, Enriquez-Sarano M, Tajik AJ, et al. Intensity of murmurs correlates with severity of valvular regurgitation. Am J Med 1996; 100:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/12\">",
"      Otto CM. Clinical practice. Evaluation and management of chronic mitral regurgitation. N Engl J Med 2001; 345:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/13\">",
"      Levine RA. Dynamic mitral regurgitation--more than meets the eye. N Engl J Med 2004; 351:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/14\">",
"      Enriquez-Sarano M, Freeman WK, Tribouilloy CM, et al. Functional anatomy of mitral regurgitation: accuracy and outcome implications of transesophageal echocardiography. J Am Coll Cardiol 1999; 34:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/15\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/16\">",
"      Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation: implications for management. Circulation 2008; 118:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/17\">",
"      Reed D, Abbott RD, Smucker ML, Kaul S. Prediction of outcome after mitral valve replacement in patients with symptomatic chronic mitral regurgitation. The importance of left atrial size. Circulation 1991; 84:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/18\">",
"      Kon MW, Myerson SG, Moat NE, Pennell DJ. Quantification of regurgitant fraction in mitral regurgitation by cardiovascular magnetic resonance: comparison of techniques. J Heart Valve Dis 2004; 13:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/19\">",
"      Buchner S, Debl K, Poschenrieder F, et al. Cardiovascular magnetic resonance for direct assessment of anatomic regurgitant orifice in mitral regurgitation. Circ Cardiovasc Imaging 2008; 1:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9705/abstract/20\">",
"      Cawley PJ, Maki JH, Otto CM. Cardiovascular magnetic resonance imaging for valvular heart disease: technique and validation. Circulation 2009; 119:468.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8116 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B987512CC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9705=[""].join("\n");
var outline_f9_30_9705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25853164\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CARDIAC AUSCULTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Heart sounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect of diagnostic maneuvers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Severity of mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cause of mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SERIAL MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25853164\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8116\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8116|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/59/12213\" title=\"diagnostic image 1\">",
"      CXR chronic MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8116|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/22/5476\" title=\"figure 1\">",
"      Mitral valve structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/62/17391\" title=\"figure 2\">",
"      Systolic murmurs and S2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8116|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?15/24/15744\" title=\"movie 1\">",
"      MR in atrial fibrillation as heard at the apex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/55/8051\" title=\"movie 2\">",
"      Mitral valve prolapse with patient standing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/37/8784\" title=\"movie 3\">",
"      Echo four chamber severe MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?16/31/16884\" title=\"movie 4\">",
"      Echo 4-chamber view MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?31/23/32115\" title=\"movie 5\">",
"      Mitral valve prolapse four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/32/8707\" title=\"movie 6\">",
"      Mitral valve prolapse bileaflet four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?23/5/23646\" title=\"movie 7\">",
"      Mitral valve prolapse apical long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?15/50/16162\" title=\"movie 8\">",
"      Mitral valve prolapse bileaflet four chamber echo with closeup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?20/12/20672\" title=\"movie 9\">",
"      MR due to mitral valve prolapse four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/39/18035\" title=\"movie 10\">",
"      TEE mitral valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?1/25/1427\" title=\"movie 11\">",
"      Mitral valve endocarditis healed parasternal long axis echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?15/52/16194\" title=\"movie 12\">",
"      MR from perforated leaflet transesophageal echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?2/1/2064\" title=\"movie 13\">",
"      TEE mitral valve leaflet perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?36/9/37010\" title=\"movie 14\">",
"      MR from perforated leaflet transesophageal color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?16/48/17154\" title=\"movie 15\">",
"      Flail mitral leaflet apical long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?12/21/12628\" title=\"movie 16\">",
"      Flail mitral valve four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/43/18099\" title=\"movie 17\">",
"      Flail mitral leaflet apical long axis color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?24/60/25539\" title=\"movie 18\">",
"      Echo parasternal long axis post MI MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?28/11/28850\" title=\"movie 19\">",
"      Echo MR in MI apical long axis color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?33/59/34740\" title=\"movie 20\">",
"      Echo MR post MI four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8116|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/20/18765\" title=\"table 1\">",
"      Causes of chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/56/26508\" title=\"table 2\">",
"      ACC AHA murmurs interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/4/36939\" title=\"table 3\">",
"      Echo asymptomatic murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/34/3628\" title=\"table 4\">",
"      TTE in chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/15/30971\" title=\"table 5\">",
"      TEE in chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/11/38075\" title=\"table 6\">",
"      Cardiac cath chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/46/35564\" title=\"table 7\">",
"      Severity of MR in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/4/29772\" title=\"table 8\">",
"      Coronary angio valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8116|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?13/4/13376\" title=\"waveform 1\">",
"      Pressures mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/23/37234\" title=\"waveform 2\">",
"      Left right atrial pressures MR",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=related_link\">",
"      Indications for corrective surgery in severe chronic primary mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37801?source=related_link\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=related_link\">",
"      Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36901?source=related_link\">",
"      Pathophysiology and stages of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=related_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=related_link\">",
"      Patient information: Mitral regurgitation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=related_link\">",
"      Surgical procedures for severe chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=related_link\">",
"      Three-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42040?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of mitral valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1528?source=related_link\">",
"      Valvular heart disease induced by drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_30_9706="Approach to the child with fever of unknown origin";
var content_f9_30_9706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with fever of unknown origin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/30/9706/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9706/contributors\">",
"     Debra L Palazzi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/30/9706/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9706/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9706/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9706/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/30/9706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/30/9706/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/30/9706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a common presenting complaint in children, accounting for nearly one-third of pediatric outpatient visits in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/1\">",
"     1",
"    </a>",
"    ]. The specific entity of \"fever of unknown origin\" (FUO), as opposed to \"fever without a source\" (FWS), has occupied a special place within infectious diseases since the first definition of and series about FUO by Petersdorf and Beeson in 1961 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the original definition has been modified, the assessment of broad categories of illness (including infections, connective tissue disease, and malignancy) as a cause of FUO remains useful.",
"   </p>",
"   <p>",
"    An approach to FUO in children will be reviewed here. Etiologies of pediatric FUO, FWS, and fever in unique host groups (eg, newborns, neutropenic children, or those with human immunodeficiency virus [HIV] infection) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"     \"Etiologies of fever of unknown origin in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term fever of unknown origin (FUO) initially was reserved for adults with fever &gt;38.4&ordm;C (101.2&ordm;F) on at least several measurements over three or more weeks without an established cause after at least one week of investigation in the hospital. This exacting definition probably was never rigorously applied in pediatrics.",
"   </p>",
"   <p>",
"    We apply the following definitions for FUO and fever without a source (FWS):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FUO &ndash; Children with fever &gt;101&ordm;F (38.3&ordm;C) of at least eight days' duration, in whom no diagnosis is apparent after initial outpatient or hospital evaluation that includes a careful history and physical examination and initial laboratory assessment.",
"     </li>",
"     <li>",
"      FWS &ndash; Children with fever lasting for one week or less without adequate explanation after a careful history and thorough physical examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"       \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"       \"Fever without a source in children 3 to 36 months of age\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above definition of FUO is a reasonable working definition for clinical purposes. However, an agreed-upon definition has not been used in published studies of FUO in children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. The required duration of fever for inclusion in various case series has ranged from five to seven days to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. Some series used different durations depending upon the setting (inpatient versus outpatient) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Several made a distinction between FUO and \"prolonged fever\" [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FUO should be distinguished from FWS for three important reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The differential diagnoses and most frequent causes of each entity are distinct",
"     </li>",
"     <li>",
"      Children with FWS usually require immediate testing and evaluation, whereas those with FUO generally do not need an emergency assessment",
"     </li>",
"     <li>",
"      Expectant antibiotic therapy is not typically indicated in children with FUO, whereas treatment generally is recommended in a select group of infants with FWS",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of infectious and noninfectious etiologies of fever of unknown origin (FUO) in children is extensive (",
"    <a class=\"graphic graphic_table graphicRef69379 \" href=\"UTD.htm?41/32/42509\">",
"     table 1",
"    </a>",
"    ). FUO is usually caused by common disorders, often with an unusual presentation. This has been illustrated in several series of FUO in children, in which rare disorders (eg, Beh&ccedil;et syndrome, ichthyosis) are exceedingly uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/4-14\">",
"     4-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"     \"Etiologies of fever of unknown origin in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious diseases and connective tissue diseases are the most common etiologic categories of FUO in children; neoplastic disorders are less common and usually have manifestations other than fever [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/4-14\">",
"     4-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many cases, a definitive diagnosis is never established and fever resolves. In more recent series, there has been a trend toward an increasing proportion of undiagnosed cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/10,13,14\">",
"     10,13,14",
"    </a>",
"    ]. Many of the classic FUO case series in children were published before the routine availability of sophisticated diagnostic testing methods that are currently available [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/3-6,12\">",
"     3-6,12",
"    </a>",
"    ]. With advances in diagnostic testing, children with diseases previously common in FUO series are now diagnosed earlier in their course of illness, leaving increasing numbers of children with difficult-to-diagnose conditions in FUO series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless the child appears acutely ill, the evaluation of fever of unknown origin (FUO) usually begins as an outpatient. If outpatient investigation fails to disclose a cause for the fever, admission to the hospital provides an opportunity to review the detailed history, physical examination, and available laboratory data, and to observe the child in a controlled setting.",
"   </p>",
"   <p>",
"    Performing a detailed and thorough history and physical examination is the first and most important component of the diagnostic evaluation of the child with FUO. Incomplete histories, ignored physical findings, and failure to correctly interpret existing laboratory data delayed accurate diagnoses in a number of series of pediatric FUO cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinician must be prepared to repeat the clinical assessment on multiple occasions to reassess historical features or clinical findings that might have been missed previously. A patient or parent eventually may recall information that was omitted, forgotten, or deemed unimportant when the initial history was obtained. New physical findings can appear, and subtle abnormalities not originally appreciated can become apparent. In one of the pediatric FUO series, significant physical findings that were not present at the time of admission developed in more than 25 percent of children during hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that some basic tests be performed in the initial evaluation of all children with FUO. Subsequent diagnostic testing is guided by \"potential diagnostic clues\" from the serial clinical assessments and initial laboratory and radiographic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Diagnostic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever of unknown origin (FUO) is usually caused by common disorders, often with an unusual presentation. Although it is important to ask questions related to uncommon diseases, an uncommon presentation of a common entity always should be entertained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential to obtain as much detail about the fever as possible. Important aspects include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The duration, height, and pattern; parents can mistake normal variations in body temperature (eg, temperature elevations after exercise or late in the afternoon) for febrile episodes.",
"     </li>",
"     <li>",
"      How was the fever assessed (eg, by touch, forehead strip, or measured with a thermometer; if measured with a thermometer, which type was used)? Rectal temperature is most accurate; however, in an older child, temperature recorded with an oral thermometer is usually adequate.",
"     </li>",
"     <li>",
"      Was the fever confirmed by someone other than the caregiver?",
"     </li>",
"     <li>",
"      Are there specific circumstances that precede the temperature elevation?",
"     </li>",
"     <li>",
"      Does the child appear ill or develop any signs or symptoms during the febrile episode? Absence of malaise or other generalized signs in a child with a history of high fevers can signal factitious fever.",
"     </li>",
"     <li>",
"      Whether and how quickly the fever responds to antipyretic drugs and whether other constitutional symptoms (eg, myalgias, headache, malaise, etc.) persist when the fever abates; the persistence of constitutional symptoms is more worrisome. Lack of response to nonsteroidal-antiinflammatory antipyretics may indicate a noninflammatory condition as the cause of FUO (eg, dysautonomia, ectodermal dysplasia, thalamic dysfunction, diabetes insipidus) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Is there associated sweating? Patients with fever, sweating, and heat intolerance may have hyperthyroidism, whereas those with fever, heat intolerance, and absence of sweating may have ectodermal dysplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H35#H35\">",
"       \"The genodermatoses\", section on 'Ectodermal dysplasias'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fever pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern and duration of fever generally are not useful in making a specific diagnosis in children with FUO [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. However, the fever pattern, such as that observed in cases of malaria, occasionally can be illuminating. It is best documented by asking the family to keep a fever diary.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermittent &ndash; Intermittent fevers with a high spike and rapid defervescence (often termed a hectic or spiking fever) suggest pyogenic infection but also can occur in patients with tuberculosis, lymphoma, and juvenile idiopathic arthritis (JIA, formerly juvenile rheumatoid arthritis, or JRA). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link\">",
"       \"Tuberculosis disease in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link\">",
"       \"Overview of Hodgkin lymphoma in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"       \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Remittent &ndash; Remittent fevers are characterized by fluctuating peaks and a baseline that does not return to normal; they can appear to be intermittent if antipyretic agents are administered. Remittent fevers are seen most commonly with viral infections but also may occur with bacterial infections (especially endocarditis), sarcoid, lymphoma, and atrial myxoma.",
"     </li>",
"     <li>",
"      Sustained &ndash; Sustained fevers persist with little or no fluctuation but can appear to be intermittent if antipyretic agents are administered. Typhoid fever, typhus, brucellosis, and many other infections characteristically follow this pattern. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link\">",
"       \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Relapsing &ndash; Relapsing fevers with periods during which patients are afebrile for one or more days between febrile episodes may be seen with malaria, rat-bite fever, Borrelia infection, and lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"       \"Clinical manifestations of malaria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1413?source=see_link\">",
"       \"Rat bite fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15033?source=see_link\">",
"       \"Clinical features, diagnosis, and management of relapsing fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link\">",
"       \"Overview of Hodgkin lymphoma in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent &ndash; Recurrent episodes of fever over periods of more than six months' duration suggest metabolic defects, central nervous system (CNS) dysregulation of temperature control, periodic disorders (such as cyclic neutropenia, hyperimmunoglobulin D syndrome, and deficiencies of selected interleukin receptor sites), and immunodeficiency states. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link&amp;anchor=H25#H25\">",
"       \"Etiologies of fever of unknown origin in children\", section on 'Other causes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Associated complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to ask, and ask again, about past or current abnormalities or complaints. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red eyes that resolved spontaneously may suggest Kawasaki disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nasal discharge may suggest sinusitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H9#H9\">",
"       \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Acute bacterial rhinosinusitis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Recurrent pharyngitis with ulcerations may suggest the periodic fever with aphthous stomatitis, pharyngitis, and adenitis syndrome (PFAPA) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=see_link\">",
"       \"Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gastrointestinal complaints may suggest Salmonellosis, an intraabdominal abscess, hepatosplenic cat scratch, or inflammatory bowel disease",
"     </li>",
"     <li>",
"      Limb or bone pain may suggest leukemia, osteomyelitis, or infantile cortical hyperostosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11641?source=see_link&amp;anchor=H14#H14\">",
"       \"Differential diagnosis of the orthopedic manifestations of child abuse\", section on 'Infantile cortical hyperostosis (Caffey disease)'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to ask specifically about the following exposures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contact with infected or otherwise ill persons.",
"     </li>",
"     <li>",
"      Exposure to animals, including household pets, domestic animals in the community, and wild animals (",
"      <a class=\"graphic graphic_table graphicRef71081 \" href=\"UTD.htm?7/37/7774\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=see_link\">",
"       \"Zoonoses from cats\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=see_link\">",
"       \"Zoonoses from dogs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26986?source=see_link\">",
"       \"Zoonoses from pets other than dogs and cats\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=see_link\">",
"       \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Travel history (including place of residence), extending back to birth. A number of diseases acquired in endemic areas can reemerge years after departure (eg, histoplasmosis, coccidioidomycosis, blastomycosis, malaria). The travel history should include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The site(s) of travel",
"     </li>",
"     <li>",
"      Prophylactic medications and immunizations before travel",
"     </li>",
"     <li>",
"      Measures taken to prevent exposure to contaminated food and water",
"     </li>",
"     <li>",
"      Whether artifacts, rocks, or soil from other geographic areas were brought into the home",
"     </li>",
"     <li>",
"      Exposure to other persons with a recent history of travel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tick bites can be a clue to Rocky Mountain spotted fever, ehrlichiosis, tularemia, tick-borne relapsing fever, or Lyme disease. North American mosquitoes and some ticks carry a variety of arboviruses. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Consumption of game meat, raw meat, or raw shellfish may be a clue to brucellosis, toxoplasmosis, tularemia, or hepatitis.",
"     </li>",
"     <li>",
"      A history of pica, specifically eating dirt, may be associated with diseases such as visceral larva migrans and toxoplasmosis.",
"     </li>",
"     <li>",
"      Exposure to medications (including prescription, topical, and nonprescription drugs) and nutritional supplements. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=see_link\">",
"       \"Drug fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of surgical procedures; patients with a history of abdominal surgery have an increased risk of developing an intraabdominal abscess.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ethnic or genetic background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain conditions associated with fever tend to occur among members of certain ethnic groups. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrogenic diabetes insipidus in Ulster Scots [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/19\">",
"       19",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"       \"Diagnosis of polyuria and diabetes insipidus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Familial Mediterranean fever in those of Sephardic Jewish, Armenian, Turkish, and Arab descent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"       \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Familial dysautonomia in those of Ashkenazi Jewish decent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with fever of unknown origin (FUO) should be evaluated while febrile. This is necessary to assess how ill the patient appears, to determine the effect of fever on sweating and the heart and respiratory rates, and to document any accompanying symptoms (eg, malaise or myalgias) or signs. The rash of juvenile idiopathic arthritis (JIA) is characteristically evanescent and may be present only during fever (",
"    <a class=\"graphic graphic_picture graphicRef62959 \" href=\"UTD.htm?13/24/13711\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The physical examination should begin with a general assessment of the patient's appearance, activity, vital signs, and growth parameters. Although it is important to evaluate the patient for weight loss, this is a nonspecific finding. Certain chronic diseases, such as inflammatory bowel disease (IBD), or endocrine abnormalities, such as pituitary gland impairment related to an intracranial lesion, characteristically result in disproportionate deceleration of linear growth or short stature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of short stature\", section on 'Diseases that may cause growth failure and short stature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain findings on physical examination help to signal a variety of conditions, as those described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skin and scalp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin lesions, abnormalities, and rashes are a component of a number of conditions that may cause FUO; if skin findings are not present initially, the skin should be examined repeatedly. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The absence of sweat during fever may suggest dehydration related to diabetes insipidus, ectodermal dysplasia, or familial dysautonomia",
"     </li>",
"     <li>",
"      Petechiae in infectious endocarditis (IE), bacteremia, and viral and rickettsial infections",
"     </li>",
"     <li>",
"      The rash of Rocky Mountain spotted fever, which typically begins on the ankles and wrists and spreads to the palms and soles and centrally (",
"      <a class=\"graphic graphic_picture graphicRef58061 \" href=\"UTD.htm?39/20/40270\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Papular lesions in cat scratch disease (",
"      <a class=\"graphic graphic_picture graphicRef78770 \" href=\"UTD.htm?7/60/8128\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eschar in tularemia (",
"      <a class=\"graphic graphic_picture graphicRef51005 \" href=\"UTD.htm?25/51/26418\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Erythema migrans or erythema migrans-like rashes in tick-borne diseases: Lyme disease (",
"      <a class=\"graphic graphic_picture graphicRef62480 graphicRef57414 \" href=\"UTD.htm?25/29/26067\">",
"       picture 5A-B",
"      </a>",
"      ) and southern tick-associated rash illness (",
"      <a class=\"graphic graphic_picture graphicRef60256 \" href=\"UTD.htm?32/19/33086\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The macular salmon-pink rash of JIA (",
"      <a class=\"graphic graphic_picture graphicRef62959 \" href=\"UTD.htm?13/24/13711\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Malar erythema in systemic lupus erythematosus (SLE) (",
"      <a class=\"graphic graphic_picture graphicRef75781 graphicRef55875 \" href=\"UTD.htm?36/46/37608\">",
"       picture 7A-B",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      Palpable purpuric lesions in vasculitis (eg, polyarteritis nodosa) (",
"      <a class=\"graphic graphic_picture graphicRef78697 \" href=\"UTD.htm?9/36/9794\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Urticarial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serpiginous macular rash and band of erythema at the lateral aspects of the hands and feet (",
"      <a class=\"graphic graphic_picture graphicRef61556 \" href=\"UTD.htm?34/7/34929\">",
"       picture 9",
"      </a>",
"      ) in serum sickness",
"     </li>",
"     <li>",
"      Erythema nodosum (",
"      <a class=\"graphic graphic_picture graphicRef80056 \" href=\"UTD.htm?8/46/8943\">",
"       picture 10",
"      </a>",
"      ) may be present in children with infection, JIA, SLE, malignancy, and inflammatory bowel disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link\">",
"       \"Erythema nodosum\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A seborrheic rash can indicate histiocytosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link&amp;anchor=H452648848#H452648848\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Skin and oral mucosa'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sparse hair, particularly of the eyebrows and eyelashes, and hypohidrosis may suggest anhidrotic ectodermal dysplasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H35#H35\">",
"       \"The genodermatoses\", section on 'Ectodermal dysplasias'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients with familial dysautonomia may have blotchy skin and multiple areas of skin trauma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eye examination may provide a number of potential diagnostic clues, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpebral conjunctivitis: Infectious mononucleosis, Newcastle disease (a viral infection associated with exposure to chickens or other birds)",
"     </li>",
"     <li>",
"      Bulbar conjunctivitis: Leptospirosis, Kawasaki disease (",
"      <a class=\"graphic graphic_picture graphicRef78898 \" href=\"UTD.htm?15/1/15376\">",
"       picture 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Phlyctenular conjunctivitis (with small, white, elevated lesions): Tuberculosis (TB)",
"     </li>",
"     <li>",
"      Ischemic retinopathy with hemorrhages and retinal detachment, ischemic optic neuropathy: Polyarteritis nodosa [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Absence of the pupillary constrictor response: Hypothalamic or autonomic dysfunction",
"     </li>",
"     <li>",
"      Absent tears and corneal reflexes: Familial dysautonomia (Riley-Day syndrome)",
"     </li>",
"     <li>",
"      Abnormal funduscopic examination: Miliary TB (choroid tubercles) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61826 \" href=\"UTD.htm?9/44/9920\">",
"       image 1",
"      </a>",
"      ), toxoplasmosis (raised yellow-white, cottony lesions in a nonvascular distribution) (",
"      <a class=\"graphic graphic_picture graphicRef69853 \" href=\"UTD.htm?20/40/21120\">",
"       picture 12",
"      </a>",
"      ), vasculitis (",
"      <a class=\"graphic graphic_picture graphicRef54347 \" href=\"UTD.htm?43/0/44046\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sinuses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sinuses should be palpated in patients with purulent or persistent nasal discharge; tenderness may suggest a diagnosis of sinusitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Oropharynx",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of dentition and other lesions in the oropharynx may provide important clues to the underlying cause of fever. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharyngeal hyperemia without exudate occasionally can be the only sign of infectious mononucleosis caused by Epstein-Barr virus (EBV) or cytomegalovirus (CMV), toxoplasmosis, tularemia, or leptospirosis.",
"     </li>",
"     <li>",
"      Dental abscess and other oral or facial infections can cause persistent fever [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]. Oral infections also can be associated with other infections (eg, sinusitis, brain abscess, mediastinal abscess).",
"     </li>",
"     <li>",
"      Anomalous dentition (hypodontia, adontia, or conical \"peg teeth\") is a characteristic of anhidrotic ectodermal dysplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H35#H35\">",
"       \"The genodermatoses\", section on 'Ectodermal dysplasias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A smooth tongue that lacks fungiform papillae or excessive salivation may suggest familial dysautonomia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with leukemia or Langerhans cell histiocytosis can have gingival hypertrophy or inflammation and loosening or loss of teeth. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link&amp;anchor=H452648848#H452648848\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Skin and oral mucosa'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;May be enlarged and tender to palpation in a number of conditions, including Kikuchi-Fujimoto disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes of peripheral lymphadenopathy in children\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the chest may reveal findings consistent with pneumonia. The presence of a cardiac murmur, especially one of new onset, may suggest infective endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=see_link\">",
"     \"Infective endocarditis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic or splenic enlargement is common in infections of the reticuloendothelial system (salmonellosis, brucellosis, etc), cat scratch disease, infective endocarditis, malaria, and many others. Tenderness on palpation of the liver edge may be noted in patients with liver abscess or cat scratch disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bones and muscles should be palpated for tenderness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tenderness over a bone can indicate the presence of osteomyelitis, malignant invasion of the bone marrow, or infantile cortical hyperostosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11641?source=see_link&amp;anchor=H14#H14\">",
"       \"Differential diagnosis of the orthopedic manifestations of child abuse\", section on 'Infantile cortical hyperostosis (Caffey disease)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Muscle tenderness can be found in trichinellosis, various arboviral infections, dermatomyositis, or polyarteritis. Tenderness over the trapezius muscle may indicate subdiaphragmatic abscess [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/12\">",
"       12",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=see_link\">",
"       \"Trichinellosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=see_link\">",
"       \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperactive deep tendon reflexes may suggest hyperthyroidism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypoactive deep tendon reflexes may suggest familial dysautonomia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Genitourinary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with FUO should have a careful rectal, external genitalia, and pelvic examination (for sexually active female adolescents). The rectal examination is performed to evaluate the patient for perirectal tenderness or a mass, which can indicate a pelvic abscess or tumor. Stool should be examined for occult blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory and imaging evaluations for fever of unknown origin (FUO) should be directed toward the likely causes of fever based upon the patient's age, duration of fever, and findings from the history and physical examination. In a review of 40 children with FUO referred to a pediatric rheumatology clinic (presumably after the more common causes of FUO had been ruled out), results of laboratory, radiologic, and pathologic studies were occasionally abnormal, but none of the tests resulted in a specific diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tempo of the evaluation is dictated by the appearance of the patient. The pace should be rapid if the child appears severely ill. It can be more deliberate if the child is less ill appearing. Sometimes the fever resolves without explanation before invasive diagnostic testing is undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Initial tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the following tests for",
"    <strong>",
"     all",
"    </strong>",
"    children with FUO:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count (CBC) and careful examination of the peripheral smear",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      Aerobic blood cultures",
"     </li>",
"     <li>",
"      Urinalysis and urine culture",
"     </li>",
"     <li>",
"      Chest radiograph",
"     </li>",
"     <li>",
"      Tuberculin skin testing",
"     </li>",
"     <li>",
"      Serum electrolytes, blood urea nitrogen (BUN), creatinine, and hepatic enzymes",
"     </li>",
"     <li>",
"      HIV serology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional tests may be indicated depending upon the presence of clues from the history, examination, or initial tests. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Additional tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CBC, differential, and smear &ndash; The CBC and smear are to evaluate the child for anemia and thrombocytosis or thrombocytopenia. Anemia may be a clue to malaria, infective endocarditis, IBD, SLE, or tuberculosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/28\">",
"       28",
"      </a>",
"      ]. Thrombocytosis is a nonspecific acute phase reactant, but it can be a clue to Kawasaki disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The total white blood cell count (WBC) and the differential generally are less helpful, although children with &gt;10,000 polymorphonuclear leukocytes (PMN) or 500 nonsegmented",
"      <span class=\"nowrap\">",
"       neutrophils/mm3",
"      </span>",
"      had a greater risk of severe bacterial infection in some series [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. If atypical lymphocytes are present, a viral infection is likely; bizarre or immature forms should prompt further evaluation for leukemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Eosinophilia may be a clue to parasitic, fungal, neoplastic, allergic, or immunodeficiency disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"       \"Approach to the patient with eosinophilia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=see_link\">",
"       \"Drug fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ESR and CRP &ndash; The ESR and CRP are nonspecific acute phase reactants but serve as general indicators of inflammation. An elevated ESR or CRP makes factitious fever less likely. Following the course of an elevated ESR or CRP assists in monitoring disease progress. A normal ESR or CRP can slow the pace of more invasive investigation. However, ESR or CRP may be normal in noninflammatory conditions associated with FUO (eg, dysautonomia, ectodermal dysplasia, thalamic dysfunction, diabetes insipidus, drug fever) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/18\">",
"       18",
"      </a>",
"      ]. The ESR also may be lowered artifactually in conditions involving consumption of fibrinogen (such as disseminated intravascular coagulopathy), and may be raised in non-inflammatory disorders characterized by hypergammaglobulinemia.",
"     </li>",
"     <li>",
"      Blood cultures &ndash; Routine blood cultures should be obtained from all patients. Several sets of blood cultures should be obtained over 24 hours in patients in whom infective endocarditis is being considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=see_link\">",
"       \"Infective endocarditis in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The use of special media or environmental conditions or holding blood cultures in the laboratory for a longer-than-normal period of incubation is valuable in select cases. These techniques can facilitate the isolation of anaerobes,",
"      <em>",
"       Brucella",
"      </em>",
"      ,",
"      <em>",
"       Leptospira",
"      </em>",
"      , and",
"      <em>",
"       Spirillum",
"      </em>",
"      .",
"     </li>",
"     <li>",
"      Urinalysis and urine culture &ndash; Urinalysis and urine culture are important diagnostic tests; urinary tract infection (UTI) is among the most frequent causes of FUO in children [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/8,10,11\">",
"       8,10,11",
"      </a>",
"      ]. In one series, the two most frequent laboratory errors were failure to perform a urinalysis and failure to adequately pursue the finding of pyuria [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/5\">",
"       5",
"      </a>",
"      ]. Sterile pyuria can be a clue to Kawasaki disease, adjacent intraabdominal infection, or genitourinary tuberculosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14005?source=see_link\">",
"       \"Renal disease in tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest radiograph &ndash; Patients with FUO should have a chest radiograph to evaluate for infiltrates and lymphadenopathy.",
"     </li>",
"     <li>",
"      PPD &ndash; All patients should have an intradermal intermediate-strength purified protein derivative (PPD)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      . Control skin testing is of limited value and is not recommended by most experts since patients with TB may have a positive control and negative PPD [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/31-34\">",
"       31-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum electrolytes, blood urea nitrogen (BUN), creatinine, and hepatic enzymes &ndash; Serum electrolytes, blood urea nitrogen (BUN), creatinine, and hepatic enzymes are obtained to evaluate renal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatic involvement. Hypernatremia may suggest diabetes insipidus; elevated hepatic enzymes may be a clue to a viral infection without distinctive features (eg, Epstein-Barr virus, cytomegalovirus), or brucellosis.",
"     </li>",
"     <li>",
"      HIV serology &ndash; HIV serology is suggested since the manifestations of primary HIV infection can be highly variable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other tests may be indicated in patients with clues from the history or physical, or abnormalities on general tests described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Laboratory tests",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stool studies &ndash; Stool cultures or examination for ova and parasites may be warranted in patients with loose stools or recent travel.",
"     </li>",
"     <li>",
"      Bone marrow - Bone marrow examination in children is most useful in diagnosing cancer (especially leukemia), histiocytic disorders, and hemophagocytic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/35\">",
"       35",
"      </a>",
"      ]. It is not generally helpful in identifying infection.",
"      <br/>",
"      <br/>",
"      In one review of 414 bone marrow examinations for the evaluation of FUO in children, an organism (",
"      <em>",
"       Salmonella",
"      </em>",
"      group D) was recovered from the bone marrow but no other site in only one case [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/36\">",
"       36",
"      </a>",
"      ]. By contrast, bone marrow results established noninfectious diagnoses in 8 percent of cases, including malignancy (6.7 percent), hemophagocytic syndromes (0.7 percent), histiocytosis (0.5 percent), and hypoplastic anemia (0.2 percent). Most of these disorders were suspected from clinical clues before the bone marrow examination was performed.",
"     </li>",
"     <li>",
"      Serologies &ndash; We suggest a targeted approach to serologic studies in children with FUO. As discussed above, we recommend HIV serology for all children with FUO since primary HIV has many manifestations. Serologic testing for syphilis should be performed in neonates, young infants, and adolescents with FUO. Other serologies that may be warranted, depending upon the case, include brucellosis, tularemia, EBV, CMV, toxoplasmosis, bartonellosis, and certain fungal infections.",
"      <br/>",
"      <br/>",
"      Serologies also can be useful for some parasitic infections such as extraintestinal amebiasis or strongyloidiasis and in other viral infections, such as lymphocytic choriomeningitis virus. Serology cannot be applied to most enteroviruses since there are too many different serotypes for general screening.",
"     </li>",
"     <li>",
"      Serum antinuclear antibody &ndash; Serum antinuclear antibody should be obtained for children older than five years of age with a strong family history of rheumatologic disease. A positive antinuclear antibody test suggests the presence of an underlying connective tissue disorder, particularly systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link&amp;anchor=H2#H2\">",
"       \"Measurement and clinical significance of antinuclear antibodies\", section on 'Diseases associated with a positive ANA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunoglobulins &ndash; Serum concentrations of IgG, IgA, and IgM should be measured in children with evidence of recurrent or persistent infection and in those with persistent fever and a negative initial evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/12\">",
"       12",
"      </a>",
"      ]. Low concentrations may indicate an immunodeficiency. Elevated levels also can be a clue, suggesting deficiency in another arm of the immune system, chronic infection, or an autoimmune disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"       \"Approach to the child with recurrent infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link&amp;anchor=H5#H5\">",
"       \"Primary humoral immune deficiencies: An overview\", section on 'Hyperimmunoglobulin M syndromes'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      IgE levels are unlikely to be helpful unless there is evidence of allergy or infection, suggesting the hyperimmunoglobin E syndrome (eg, eosinophilia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=see_link\">",
"       \"Hyperimmunoglobulin E syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Serum IgD levels should be obtained in patients with periodic or intermittent fever. Specific molecular genetic tests for other periodic disorders are available but should probably be obtained only after consultation with an expert in these conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=see_link\">",
"       \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"       \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Molecular testing &ndash; In certain cases, molecular testing (eg, polymerase chain reaction) can be useful. Examples include EBV, CMV, parvovirus, and Bartonella. (See appropriate topic reviews).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most difficult decisions is when to pursue additional imaging in patients with FUO. Diagnostic imaging of the nasal sinuses, mastoids, and gastrointestinal (GI) tract should be performed initially only for specific indications, but may be warranted in children in whom FUO persists without explanation for a long period.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal imaging &ndash; Children with persistent fever, elevated ESR or CRP, anorexia, and weight loss should have studies to exclude inflammatory bowel disease, particularly if they also have abdominal complaints with or without anemia. However, imaging of the GI tract also should be pursued eventually in children whose fevers persist without other explanation and may be caused by conditions such as psoas abscess or cat scratch disease. Ultrasonography, computed tomographic (CT) scanning, and magnetic resonance imaging (MRI) can be useful in evaluating the abdomen [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/38\">",
"       38",
"      </a>",
"      ]. These tests can detect abscesses, tumors, and lymphadenopathy.",
"     </li>",
"     <li>",
"      CNS imaging &ndash; Imaging of the CNS with or without an electroencephalogram generally is not helpful in the evaluation of children with FUO.",
"     </li>",
"     <li>",
"      WBC scans &ndash; Gallium and indium-111-labeled WBC scanning can highlight inflammatory lesions and tumors and provide noninvasive screening of the entire body [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/39\">",
"       39",
"      </a>",
"      ]. However, these tests are not diagnostic, and follow-up with other imaging studies is required. One group found that radionuclide scans seldom revealed an unsuspected diagnosis in children with FUO [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/37\">",
"       37",
"      </a>",
"      ]. Another found that gallium scanning can be helpful when there is suspicion of localized infection but is unlikely to be helpful in those with only systemic signs [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other imaging techniques &ndash; A number of other imaging techniques, including radiographic bone survey, technetium bone scan, and liver-spleen scan can be employed in selected cases when a thorough evaluation has failed to reveal the cause of FUO and suspicion for a source that could be revealed by these tests exists.",
"     </li>",
"     <li>",
"      PET scans &ndash; Positron emission tomography (PET) scanning is another technique that may be helpful in patients with persistent FUO who remain without a diagnosis after initial evaluation. In a review of prospective studies, (18)F-FDG PET contributed to the diagnosis in 25 to 69 percent of cases of FUO [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/41\">",
"       41",
"      </a>",
"      ]. (18)F-FDG PET was more sensitive than Ga-citrate SPECT in detecting tumors, infection, and inflammation.",
"      <br/>",
"      <br/>",
"      Studies of PET scans in the evaluation of FUO in children are limited. One group studied PET in 11 children with FUO awaiting liver transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/42\">",
"       42",
"      </a>",
"      ]. The scans were positive in five, all of whom had positive bacterial cultures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      histologic evidence of infection in the excised liver; other scanning procedures in these children had been negative. PET scans were negative in the other six children, none of whom had evidence of infection in the liver at the time of transplant.",
"     </li>",
"     <li>",
"      Immunoscintigraphy &ndash; Immunoscintigraphy is another technique that may be helpful in certain patients with persistent FUO who remain without a diagnosis after initial evaluation. In 30 neonates and infants with FUO, immunoscintigraphy with labeled antigranulocyte antibody had a sensitivity and specificity of 72 and 95 percent, respectively, for detection of infection (as verified by conventional radiography, MRI, CT, biopsy, blood culture, and clinical follow-up) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other evaluations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrocardiography and echocardiography should be obtained in patients with positive blood cultures and suspicion for infective endocarditis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=see_link\">",
"       \"Infective endocarditis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ophthalmologic examination by slit lamp is useful in some patients with FUO to evaluate the presence of uveitis or leukemic infiltration",
"     </li>",
"     <li>",
"      Biopsy (eg, of lymph nodes or liver) should be reserved for children with evidence of involvement of specific organs",
"     </li>",
"     <li>",
"      Sophisticated abdominal imaging procedures largely have eliminated the need for exploratory laparoscopy or laparotomy in the evaluation of children with FUO",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     EMPIRICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empirical treatment with antiinflammatory medications or antibiotics generally should be avoided as diagnostic measures in children with fever of unknown origin (FUO). Exceptions include nonsteroidal agents in children with presumed juvenile idiopathic arthritis (JIA) and antituberculous drugs in critically ill children with possible disseminated tuberculosis (TB).",
"   </p>",
"   <p>",
"    Antiinflammatory drugs do not help to distinguish fevers of infections from those of noninfectious causes. Empirical trials of broad-spectrum antibiotics can mask or delay the diagnosis of important infections, such as meningitis, parameningeal infection, infectious endocarditis, or osteomyelitis. Use of empirical antibiotics also can hamper the ability to isolate an organism from the blood or a specific site if further culturing is warranted as the evaluation proceeds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to adults, most children with fever of unknown origin (FUO) have treatable or self-limited diseases. The fever resolves over time in most cases, and a specific diagnosis eventually can be made in others [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/8,9,12,44\">",
"     8,9,12,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this fact, the overall prognosis is far from benign. In two series from the 1970s, mortality was 9 percent in one group of 100 children with FUO and 6 percent in another group of 54 children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. In more recent series, mortality is less frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Curiously, the prognosis may be better when a diagnosis cannot be established after extensive evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/5,27,44\">",
"     5,27,44",
"    </a>",
"    ]. Of those without a definitive diagnosis, many appear to do well, although episodes of fever may recur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/5,44\">",
"     5,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In long-term follow-up (median 3.5 years, range 1.2 to 5.3 years) of 19 children with FUO for at least two weeks and in whom no diagnosis was established, 16 of 19 (82 percent) were afebrile and completely well [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/44\">",
"     44",
"    </a>",
"    ]. Two patients were subsequently diagnosed with juvenile idiopathic arthritis (JIA), one shortly after discharge and one 1.5 years later. One child, who had presented with abdominal pain and fever, had two episodes of intussusception (8 and 14 months after discharge), and the authors speculate that her initial episode might have been intussusception that spontaneously reduced.",
"   </p>",
"   <p>",
"    Among 40 children who were referred for pediatric rheumatology evaluation with FUO of at least one month's duration and in whom no diagnosis was established, 37 were available for follow-up at a mean of 60.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/30/9706/abstract/27\">",
"     27",
"    </a>",
"    ]. Two children developed inflammatory bowel disease (IBD) (one 7 months and one 3.5 years after initial evaluation); in both cases, fever resolved after initiation of appropriate therapy for IBD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       \"Patient information: Fever in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"       \"Patient information: Fever in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of fever of unknown origin (FUO) should be reserved for children with fever of at least eight days' duration in whom no diagnosis is apparent after initial evaluation either in the hospital or as an outpatient. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections are the most common causes of FUO in children, followed by connective tissue disorders and neoplasms. However, in many cases, a definitive diagnosis is never established and fever resolves. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history and detailed physical examination are essential for all patients. These should be repeated on several occasions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history should include details about the fever, associated complaints, and exposures (eg, to ill contacts, animals, insects, travel, drugs). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient should be examined while febrile. Important aspects of the examination include vital signs, the skin, scalp, eyes, sinuses, oropharynx, chest, abdominal, and musculoskeletal and genitourinary systems. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following tests as part of the initial evaluation (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Initial tests'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete blood count (CBC) and peripheral smear",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      Blood cultures",
"     </li>",
"     <li>",
"      Urinalysis and urine culture",
"     </li>",
"     <li>",
"      Chest radiograph",
"     </li>",
"     <li>",
"      Tuberculin skin testing",
"     </li>",
"     <li>",
"      Serum electrolytes, blood urea nitrogen (BUN), creatinine, and hepatic enzymes",
"     </li>",
"     <li>",
"      HIV serology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional tests and imaging studies should be based upon the findings of the history, examination, and initial tests. Diagnostic imaging of the nasal sinuses, mastoids, and gastrointestinal tract may be warranted eventually in children in whom FUO persists without explanation. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Additional tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Other evaluations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric treatment with antiinflammatory medications or antibiotics generally should be avoided as diagnostic measures in children with FUO. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Empirical treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/1\">",
"      Finkelstein JA, Christiansen CL, Platt R. Fever in pediatric primary care: occurrence, management, and outcomes. Pediatrics 2000; 105:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/2\">",
"      PETERSDORF RG, BEESON PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore) 1961; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/3\">",
"      BREWIS EG. CHILD CARE IN GENERAL PRACTICE. UNDIAGNOSED FEVER. Br Med J 1965; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/4\">",
"      Lohr JA, Hendley JO. Prolonged fever of unknown origin: a record of experiences with 54 childhood patients. Clin Pediatr (Phila) 1977; 16:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/5\">",
"      McClung HJ. Prolonged fever of unknown origin in children. Am J Dis Child 1972; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/6\">",
"      Pizzo PA, Lovejoy FH Jr, Smith DH. Prolonged fever in children: review of 100 cases. Pediatrics 1975; 55:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/7\">",
"      Cogulu O, Koturoglu G, Kurugol Z, et al. Evaluation of 80 children with prolonged fever. Pediatr Int 2003; 45:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/8\">",
"      Pasic S, Minic A, Djuric P, et al. Fever of unknown origin in 185 paediatric patients: a single-centre experience. Acta Paediatr 2006; 95:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/9\">",
"      Chantada G, Casak S, Plata JD, et al. Children with fever of unknown origin in Argentina: an analysis of 113 cases. Pediatr Infect Dis J 1994; 13:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/10\">",
"      Jacobs RF, Schutze GE. Bartonella henselae as a cause of prolonged fever and fever of unknown origin in children. Clin Infect Dis 1998; 26:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/11\">",
"      Bourrillon A. [Management of prolonged fever in infants]. Arch Pediatr 1999; 6:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/12\">",
"      Feigin RD, Shearer WT. Fever of unknown origin in children. Curr Probl Pediatr 1976; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/13\">",
"      Akpede GO, Akenzua GI. Management of children with prolonged fever of unknown origin and difficulties in the management of fever of unknown origin in children in developing countries. Paediatr Drugs 2001; 3:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/14\">",
"      Schneider T, Loddenkemper C, Rudwaleit M, et al. [Fever of unknown origin in the 21st century: infectious diseases]. Dtsch Med Wochenschr 2005; 130:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/15\">",
"      Steele RW. Fever of unknown origin: a time for patience with your patients. Clin Pediatr (Phila) 2000; 39:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/16\">",
"      de Kleijn EM, van Lier HJ, van der Meer JW. Fever of unknown origin (FUO). II. Diagnostic procedures in a prospective multicenter study of 167 patients. The Netherlands FUO Study Group. Medicine (Baltimore) 1997; 76:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/17\">",
"      Gaeta GB, Fusco FM, Nardiello S. Fever of unknown origin: a systematic review of the literature for 1995-2004. Nucl Med Commun 2006; 27:205.",
"     </a>",
"    </li>",
"    <li>",
"     Long SS, Edwards KM. Prolonged, recurrent, and periodic fever syndromes. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/19\">",
"      Bichet DG, Hendy GN, Lonergan M, et al. X-linked nephrogenic diabetes insipidus: from the ship Hopewell to RFLP studies. Am J Hum Genet 1992; 51:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/20\">",
"      Akova YA, Jabbur NS, Foster CS. Ocular presentation of polyarteritis nodosa. Clinical course and management with steroid and cytotoxic therapy. Ophthalmology 1993; 100:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/21\">",
"      Hsu CT, Kerrison JB, Miller NR, Goldberg MF. Choroidal infarction, anterior ischemic optic neuropathy, and central retinal artery occlusion from polyarteritis nodosa. Retina 2001; 21:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/22\">",
"      Siminoski K. Persistent fever due to occult dental infection: case report and review. Clin Infect Dis 1993; 16:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/23\">",
"      Katz J, Weinstein E, Barak S, Livneh A. Dental disease in the differential diagnosis of fever of unknown origin. Ann Dent 1992; 51:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/24\">",
"      Naschitz JE, Yeshurun D. Occult infection in the facial area presenting as fever of unknown origin. Isr J Med Sci 1985; 21:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/25\">",
"      Levinson SL, Barondess JA. Occult dental infection as a cause of fever of obscure origin. Am J Med 1979; 66:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/26\">",
"      Arisoy ES, Correa AG, Wagner ML, Kaplan SL. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment. Clin Infect Dis 1999; 28:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/27\">",
"      Miller LC, Sisson BA, Tucker LB, Schaller JG. Prolonged fevers of unknown origin in children: patterns of presentation and outcome. J Pediatr 1996; 129:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/28\">",
"      Farid Z, Kamal M, Karam M, et al. Extra-pulmonary tuberculosis in patients with fever of unknown origin: clinical features and diagnosis. J Egypt Public Health Assoc 1999; 74:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/29\">",
"      Stein RC. The white blood cell count in fevers of unknown origin. Am J Dis Child 1972; 124:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/30\">",
"      Todd JK. Childhood infections. Diagnostic value of peripheral white blood cell and differential cell counts. Am J Dis Child 1974; 127:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/31\">",
"      Margolis MT. Specific anergy in tuberculosis. N Engl J Med 1983; 309:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/32\">",
"      McMurray DN, Echeverri A. Cell-mediated immunity in anergic patients with pulmonary tuberculosis. Am Rev Respir Dis 1978; 118:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/33\">",
"      Nash DR, Douglass JE. Anergy in active pulmonary tuberculosis. A comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. Chest 1980; 77:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/34\">",
"      Tuberculin negative tuberculosis. Am Rev Respir Dis 1973; 107:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/35\">",
"      Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis 2003; 36:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/36\">",
"      Hayani A, Mahoney DH, Fernbach DJ. Role of bone marrow examination in the child with prolonged fever. J Pediatr 1990; 116:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/37\">",
"      Steele RW, Jones SM, Lowe BA, Glasier CM. Usefulness of scanning procedures for diagnosis of fever of unknown origin in children. J Pediatr 1991; 119:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/38\">",
"      Picus D, Siegel MJ, Balfe DM. Abdominal computed tomography in children with unexplained prolonged fever. J Comput Assist Tomogr 1984; 8:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/39\">",
"      Fineman DS, Palestro CJ, Kim CK, et al. Detection of abnormalities in febrile AIDS patients with In-111-labeled leukocyte and Ga-67 scintigraphy. Radiology 1989; 170:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/40\">",
"      Buonomo C, Treves ST. Gallium scanning in children with fever of unknown origin. Pediatr Radiol 1993; 23:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/41\">",
"      Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 2007; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/42\">",
"      Sturm E, Rings EH, Sch&ouml;lvinck EH, et al. Fluordeoxyglucose positron emission tomography contributes to management of pediatric liver transplantation candidates with fever of unknown origin. Liver Transpl 2006; 12:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/43\">",
"      Gratz S, Behr TM, Herrmann A, et al. Immunoscintigraphy (BW 250/183) in neonates and infants with fever of unknown origin. Nucl Med Commun 1998; 19:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/30/9706/abstract/44\">",
"      Talano JA, Katz BZ. Long-term follow-up of children with fever of unknown origin. Clin Pediatr (Phila) 2000; 39:715.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5993 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9706=[""].join("\n");
var outline_f9_30_9706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fever pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Associated complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ethnic or genetic background",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skin and scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sinuses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Oropharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Genitourinary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Initial tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Additional tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other evaluations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      EMPIRICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5993|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/44/9920\" title=\"diagnostic image 1\">",
"      Choroidal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5993|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/24/13711\" title=\"picture 1\">",
"      Systemic onset JIA rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/20/40270\" title=\"picture 2\">",
"      RMSF rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/60/8128\" title=\"picture 3\">",
"      Cat scratch disease typical papular lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/51/26418\" title=\"picture 4\">",
"      Tularemia eschar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/16/19712\" title=\"picture 5A\">",
"      Erythema migrans bulls eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/35/575\" title=\"picture 5B\">",
"      Erythema migrans uniform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/19/33086\" title=\"picture 6\">",
"      STARI rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/39/32371\" title=\"picture 7A\">",
"      Acute cutaneous lupus erythematosus - malar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/47/3828\" title=\"picture 7B\">",
"      Acute cutaneous lupus erythematosus - malar eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9794\" title=\"picture 8\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/7/34929\" title=\"picture 9\">",
"      Serum sickness hands feet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/46/8943\" title=\"picture 10\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/1/15376\" title=\"picture 11\">",
"      Conjunctivitis in Kawasaki",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/40/21120\" title=\"picture 12\">",
"      Toxoplasma chorioretinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/0/44046\" title=\"picture 13\">",
"      Perivascular sheathing retina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5993|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/32/42509\" title=\"table 1\">",
"      Causes of FUO in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/37/7774\" title=\"table 2\">",
"      Zoonoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15033?source=related_link\">",
"      Clinical features, diagnosis, and management of relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11641?source=related_link\">",
"      Differential diagnosis of the orthopedic manifestations of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=related_link\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=related_link\">",
"      Etiologies of fever of unknown origin in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=related_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=related_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=related_link\">",
"      Infective endocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=related_link\">",
"      Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1413?source=related_link\">",
"      Rat bite fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14005?source=related_link\">",
"      Renal disease in tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=related_link\">",
"      Trichinellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=related_link\">",
"      Zoonoses from cats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=related_link\">",
"      Zoonoses from dogs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26986?source=related_link\">",
"      Zoonoses from pets other than dogs and cats",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_30_9707="Loading dose aminoglycoside";
var content_f9_30_9707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended loading dose for gentamicin or tobramycin therapy in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Desired peak concentration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Site or infection or indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loading dose, mg/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 4 &micro;g/mL",
"       </td>",
"       <td>",
"        Uncomplicated lower urinary tract infection, gram-positive endocarditis, synergy with beta-lactams for serious gram-positive infections",
"       </td>",
"       <td>",
"        0.6 to 1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 to 8&nbsp;&micro;g/mL",
"       </td>",
"       <td>",
"        Gram-negative sepsis or other serious gram-negative",
"infections",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 to 9&nbsp;&micro;g/mL",
"       </td>",
"       <td>",
"        Gram-negative pneumonia or acute life-threatening gram-negative infection in a critically ill patient",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9707=[""].join("\n");
var outline_f9_30_9707=null;
var title_f9_30_9708="Comorbid mood and anxiety";
var content_f9_30_9708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lifetime comorbid mood and anxiety disorders in US patients with marijuana dependence disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Comorbid disorder",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Subjects with marijuana dependence disorder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       SE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Any mood disorder",
"      </td>",
"      <td>",
"       60.5",
"      </td>",
"      <td>",
"       2.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Major depression",
"      </td>",
"      <td>",
"       47.0",
"      </td>",
"      <td>",
"       2.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dysthymia",
"      </td>",
"      <td>",
"       20.3",
"      </td>",
"      <td>",
"       2.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mania",
"      </td>",
"      <td>",
"       23.6",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hypomania",
"      </td>",
"      <td>",
"       10.2",
"      </td>",
"      <td>",
"       1.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Any anxiety disorder",
"      </td>",
"      <td>",
"       48.5",
"      </td>",
"      <td>",
"       2.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Panic disorder with agoraphobia",
"      </td>",
"      <td>",
"       8.8",
"      </td>",
"      <td>",
"       2.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Panic disorder without agoraphobia",
"      </td>",
"      <td>",
"       13.7",
"      </td>",
"      <td>",
"       1.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Social phobia",
"      </td>",
"      <td>",
"       21.3",
"      </td>",
"      <td>",
"       2.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Specific phobia",
"      </td>",
"      <td>",
"       27.2",
"      </td>",
"      <td>",
"       2.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Generalized anxiety disorder",
"      </td>",
"      <td>",
"       20.8",
"      </td>",
"      <td>",
"       2.6",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Conway, KP, Compton, W, Stinson, FS, Grant, BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67:247.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9708=[""].join("\n");
var outline_f9_30_9708=null;
var title_f9_30_9709="VIT schedules 2";
var content_f9_30_9709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Typical conventional dosing schedules for venom immunotherapy: Schedule 2",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Week",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Injection 1",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Injection 2",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Injection 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Concentration, micrograms/mL",
"       </td>",
"       <td class=\"subtitle2\">",
"        Volume, mL",
"       </td>",
"       <td class=\"subtitle2\">",
"        Concentration, micrograms/mL",
"       </td>",
"       <td class=\"subtitle2\">",
"        Volume, mL",
"       </td>",
"       <td class=\"subtitle2\">",
"        Concentration, micrograms/mL",
"       </td>",
"       <td class=\"subtitle2\">",
"        Volume, mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monthly",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Injections 1, 2, and 3 are given at 30 min intervals on days when more than one injection is administered (reading from left to right across table in the week 1 row). During weeks 1 through 3, the patient receives 3 injections per visit. During weeks 4 through 8, the patient receives two injections per visit. Maintenance is achieved by approximately week 8. Thereafter, the patient receives one injection per visit and the interval between visits is extended from weekly to monthly. This schedule is based upon the package insert for ALK-Abello venom extracts (Round Rock, TX).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Reproduced with permission from: Golden DBK. Insect Allergy. In: Middleton's Allergy: Principles &amp; Practice, 7th ed, Adkinson NF Jr, Bochner BS, Busse WW, et al (Eds), Mosby Elsevier, Philadelphia 2009. Illustrations used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9709=[""].join("\n");
var outline_f9_30_9709=null;
var title_f9_30_9710="Body composition of healthy children";
var content_f9_30_9710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Body composition of healthy children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gender",
"       </td>",
"       <td class=\"subtitle1\">",
"        Race/ethnicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Height (cm)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight (kg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat-free mass (kg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat mass (kg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"16\">",
"        Female",
"       </td>",
"       <td rowspan=\"4\">",
"        Multiracial",
"       </td>",
"       <td>",
"        Birth",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        9.6",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Caucasian",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        African-American",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Hispanic",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        161",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"16\">",
"        Male",
"       </td>",
"       <td rowspan=\"4\">",
"        Multiracial",
"       </td>",
"       <td>",
"        Birth",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        10.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Caucasian",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        African-American",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        161",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Hispanic",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Fomon SJ, Haschke F, Ziegler EE, Nelson SE. Am J Clin Nutr 1982; 35:1169.",
"      <br>",
"       2. Ellis KJ, Abrams SA, Wong WW. Am J Clin Nutr 1997; 65:724.",
"       <br>",
"        3. Ellis KJ. Am J Clin Nutr 1997; 66:1323.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9710=[""].join("\n");
var outline_f9_30_9710=null;
var title_f9_30_9711="Corneal pannus";
var content_f9_30_9711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal pannus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An area of corneal pannus with superficial blood vessel growth onto the inferior cornea at the 5 o'clock position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_30_9711=[""].join("\n");
var outline_f9_30_9711=null;
